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Abstract 
The management of chronic pain with opioids can cause opioid-induced analgesic 
tolerance and hyperalgesia, complicating clinical pain-management treatments. Mu 
opioid receptors (MOPs) are inhibitory G-protein coupled receptors. MOPs have been 
studied for years; however, the intracellular signaling pathways triggered by their 
activation are not well known. Research presented here sought to determine if opioid 
induced tolerance is linked to a decreased activity in the PI3K/AKT intracellular 
signaling pathway. To assess gene expression within this pathway and cGMP nucleotide 
levels, C57Bl/6 wild type male mice  were divided into saline , morphine tolerant (MT), 
and morphine tolerant with spinal nerve ligation (MT+SNL) groups. Injections were 
given subcutaneously twice a day for a total of five days. MT mice without SNL 
developed opioid induced tolerance by day 3 and opioid induced hyperalgesia by day 5. 
MT+SNL mice had lower TPWL responses for the ipsi (injured) side compared to their 
contra (uninjured) side.  
Brainstem, spinal cord, dorsal root ganglia, and sciatic nerves were harvested 
from mice on day 6 of the behavior testing and were used for qPCR gene expression 
analysis. Genes chosen for qPCR analysis were Akt1, Akt2, Akt3, Pik3cg (splice variants 
v1-v3), Pten, Abcc8, Abcc9, Kcnj11 (splice variants v1 and v2), Kcnj8, Oprm1, Jnk3, and 
nNos1. There were few significant gene expression changes of the PI3K/AKT 
intracellular signaling pathway for MT mice compared to saline mice in both the central 
and peripheral nervous system. The addition of the MT+SNL model saw larger gene 
expression increases or decreases in almost all genes, with no clear trend for gene 
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expression changes both between and within the central and peripheral nervous system 
tissues. Additionally, there was decreased gene expression in all genes except Pten in the 
MT+SNL spinal cord.  
The daily administration of PI3K/AKT pathway inhibitors, thalidomide, 
SP600125, and quercetin to MT+SNL mice attenuated the development of morphine 
tolerance, suggesting PI3K/AKT pathway activity is positively correlated with morphine 
tolerance. Thus, our initial hypothesis that stated PI3K/AKT pathway downregulation 
may contribute to morphine tolerance was not supported by our data collected from this 
study. Overall, the PI3K/AKT intracellular signaling pathway is a potential target for 
reducing the development of morphine tolerance. Continued research into this pathway, 
including further protein analysis and studies utilizing knockout mice, will advance 
understanding of morphine tolerance and potentially contribute to the development of 
new analgesic drug therapies. 
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Introduction 
Pain, a physiological phenomenon necessary for survival, can create physical and 
emotional problems when it is not treated properly and/or continues indefinitely. Defined 
by the International Association for the Study of Pain as “an unpleasant sensory and 
emotional experience associated with actual or potential tissue damage”, pain is the most 
common reason for physician visits (Bonica 1979; Debono, Hoeksema, and Hobbs 2013). 
One of the most prevalent and difficult areas of pain to treat, chronic pain,  affects almost 
one in four primary care patients around the world (van Hecke, Torrance, and Smith 
2013; Lépine and Briley 2004; Moulin et al. 2002; Pagé et al. 2018; Schopflocher, 
Taenzer, and Jovey 2011). Chronic pain is categorized as either nociceptive (pain caused 
by potentially harmful stimuli), neuropathic (pain caused by a dysfunction of the nervous 
system), psychogenic (psychological pain), or idiopathic (pain with an unknown origin) 
and is clinically defined as pain lasting at least 3 to 6 months and can profoundly affect 
one’s quality of life as it can interfere with day-to-day activities (Kuner 2010; Loeser et 
al. 2001). As of 2004, chronic pain was recognized as a disease itself and not just an 
underlying symptom of another disease (Croft, Blyth, and Van Der Windt 2010; Siddall 
and Cousins 2004).   
To improve the quality of life of someone suffering from chronic pain, doctors 
commonly prescribe analgesics such as opioids. Naturally found and extracted from the 
opium poppy Papaver somniferm, opioids can illicit various psychoactive effects on the 
brain (Hill, Hunt, and Duryea 2017). Additionally, there are various synthetic opioids 
used in a clinical setting for pain treatment including fentanyl, hydromorphone, 
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hydrocodone, oxycodone, codeine, and heroin (Hill, Hunt, and Duryea 2017). Past 
reports and surveys had reported that a patient suffering from chronic pain can be 
adequately treated using a stable dose of opioids (dosages ranging from 195 mg/day to 2 
g/day) with minimal addiction risks and side effects (Ballantyne and Mao 2003). 
Additionally, not only do the patients report improvement in their everyday life, but also 
the use of opioids in non-escalating, moderate doses are reported to not affect the 
cognitive functions of patients (Ballantyne and Mao 2003). However, not all pain is the 
same, and in the cases where opioid doses need to be escalated due to tolerance, 
complications can arise, including respiratory depression, nausea, constipation, and 
cognitive decline. In the United States alone, over 90 individuals die every day from an 
exogenous opioid related overdose (Rudd et al. 2016). With 650,000 people given both 
new and refilled opioid prescriptions daily in the United States, opioid overuse has 
become an epidemic (Centers for Disease Control 2015). A 2017 study analyzing opioid-
related fatalities found that roughly six out of ten people that overdose on opioids were 
diagnosed with chronic pain (Olfson et al. 2018). With 100 million U.S. citizens 
diagnosed with chronic pain and five to eight million of those people relying on long-
term opioid therapy, understanding the molecular changes in the nervous system that 
occur during opioid usage with and without underlying chronic pain may prove to be vital 
in helping those currently taking opioids in the long-term. 
Neuropathic pain, which appears to be opioid resistant, is defined as spontaneous 
or provoked pain caused either by a lesion or a disease affecting the somatosensory 
nervous system, affects 15 to 20 million United State citizens (~5% of the U.S. populace) 
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and can originate in either the peripheral or central nervous system (Gordon Smith and 
Robinson Singleton 2006; Portenoy, Foley, and Inturrisi 1990; Scholz et al. 2019). One 
of the big differences in neuropathic pain versus acute pain lies in the way patients 
describe their pain, as those with neuropathic pain usually as describe their pain as 
“electric,” “tingling,” and “burning” (Nee and Butler 2006). Additionally, neuropathic 
chronic pain can have profound impacts on one’s productivity and life, with recent 
studies of diabetic neuropathy finding 65% of employed respondents had either missed 
work or lost productivity due to their chronic pain (Mann et al. 2014). Animal studies 
have shown that damage to sensory fibers such as Aβ, Aδ, and C-fibers can alter ion 
channel functioning and lead to a hyperexcitability of the cell by altering signal 
transduction and transmission (Colloca et al. 2017). The nerve damage and increase in 
ion channel abundance can increase excitation in the spinal cord, leading to an increased 
signal projection to the somatosensory cortex via the spinothalamic pathway (where the 
location and intensity of pain are then perceived). While current animal model studies 
suggest that opioid resistance seen for neuropathic pain may be more relative than 
absolute, there are still many unknowns about the effectiveness of opioid therapy for 
neuropathic pain (Bian et al. 1999; Mao, Price, and Mayer 1995, see " Opioids and the 
Treatment of Neuropathic Chronic Pain"). Thus, to better understand the clinical utility 
of opioids, it is important to understand the mechanisms behind opioid signaling related 
to neuropathic chronic pain and how they compare to acute pain.  
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Opioid Signaling 
Opioid receptor signaling is vital for the regulation of both pain related behaviors 
and analgesia. Opioid receptors are broadly expressed throughout the body, in pain 
signaling (nociceptive) neuronal pathways and various areas of the central nervous 
system (CNS) involved with response-reward signaling (Al-Hasani and Bruchas 2011). 
Within these areas, there are four different known opioid receptors including mu (µ) 
(MOP), delta (δ), kappa (κ), and opioid like receptor-1 (NOP), all of which are seven 
transmembrane G-protein coupled receptors (GPCRs) (Lord et al. 1977; Martin et al. 
1976; Meunier et al. 1995). Most exogenous opioids given for analgesic purposes bind to 
the MOP, as the MOP produces a majority of the analgesic effects of prescribed opioids 
(J. B. Wang et al. 1993). Opioids also bind to δ- and κ- opioid receptors (Pasternak 1993). 
Because the MOP is the most widely studied, MOPs are the main opioid receptors 
analyzed in the following studies. 
MOP signaling is initiated by the binding of an agonist (opioid) to the receptor, 
allowing the GPCR subunits Gα and Gβγ to decouple and selectively interact with 
different pathways (Figure 1) (Al-Hasani and Bruchas 2011). The decoupling of Gα 
causes the activation of protein kinase C (PKC) and leads to the activation of protein-
coupled inwardly rectifying K+ channels such as GIRKs (Kir3.x) or KATP channels  
(Kir6.x), while the Gβγ subunit decoupling allows for the activation of voltage-gated 
Ca2+ channels to inhibit additional calcium from entering the pre-synaptic terminal 
(Dascal 1997; Nagi and Pineyro 2014). Previous studies have found when Gβγ binds to 
the Ca2+ channel, the overall voltage activation of the Ca2+ channel is reduced (Zamponi 
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and Snutch 1998; Zamponi and Snutch 2002). After the Ca2+ channel is inhibited by Gβγ 
and GIRKs and KATP channels are opened by Gα downstream signaling, the synaptic cleft 
is hyperpolarized, which prevents a nociceptive signal from reaching the brain (Figure 
2b) (Parsadaniantz et al. 2015).  
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Figure 1. General overview of opioid receptor signaling on a synaptic vesicle. Events 
of opioid signaling once activated by a mu-opioid receptor (MOP) agonist (triangles). (1) 
Agonist binds to a MOP, an inhibitory G-protein coupled receptor, which causes the G-
protein subunits to dissociate and act on various different ion channels (voltage-gated 
Ca2+, KATP, and inwardly rectifying potassium channels) and intracellular signaling 
molecules. (2) Mitogen-activated protein kinase (MAPK) signaling can also occur after 
activation or receptor phosphorylation (4). (5) Recruitment of β-arrestin, which leads to 
the internalization of the receptor (6) and potential recycling of MOPs (7). Adapted from 
(Al-Hasani and Bruchas 2011).  
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Figure 2. Illustration of pain inhibition of noxious signals from the periphery to the 
brain. After an injury, a noxious signal is sent to the dorsal root ganglia, where it then 
travels along the ascending axon in the spinal cord to the thalamus before relaying to the 
cortex. (A) represents the site of injury and initial pain signaling. After injury, immune 
cells move to the inflamed tissues and release chemokines (circles), interleukins (stars), 
cytokines, and opioids (triangles). The cytokines, interleukins, and chemokines promote 
noxious signals and maintain them, while opioids can promote analgesia by mu opioid 
receptors. (B) illustrates how opioid receptors inhibit noxious signals from continuing 
through the nervous system to the brain. The noxious signal causes a secretion of 
chemokines, which bind to chemokine receptors in the dorsal root ganglia and induce the 
release of substance P (SP), glutamate (Glu), and calcitonin gene-related peptide (CGRP) 
from the primary afferent terminal to the second-order neuron. The K+ efflux caused by 
opioid receptor activation causes hyperpolarization of the first and second-order neurons, 
promoting analgesia. The opioids can be endogenous and released from the 
periaqueductal grey (PAG) and rostral ventromedial medulla (RVM), or exogenous. 
Adapted from (Parsadaniantz et al. 2015).  
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Chronic use of Opioids and the Development of Tolerance 
While opioids are vital for extreme pain-management treatment, continued 
overuse can adversely affect the nervous system, causing neuroplastic changes in both the 
peripheral (e.g., dorsal root ganglia and sciatic nerves) and central nervous system (e.g., 
brain and spinal cord). (Gillberg and Askmark 1991; Mao and Mayer 2006; Mennicken et 
al. 2003; Snyder 1975). When MOPs are continuously stimulated through repeated opioid 
use, tolerance can develop as more opioids are needed to achieve the desired effect. This 
repeated overexposure can induce tolerance from ligands constantly binding to the 
receptor and creating a desensitization effect and/or endocytosis of the opioid receptor 
into the synaptic vesicle (Bespalov et al. 2016; Waldhoer, Bartlett, and Whistler 2004) 
(Figure 1). When analgesic tolerance begins to develop, patients may begin to self-
medicate, or their doctor may increase their dose or dose frequency of opioids. This 
process can ultimately lead to the development of additional negative effects, including 
the patient taking continually increased doses until they reach the potential for an 
overdose (taking a lethal dose of a drug) as the opioids can induce respiratory depression 
by inhibiting chemoreceptors in the medulla of the brainstem (White and Irvine 2003). 
By reducing the development of MT in patients, the need for dose escalation would be 
negated, leading to a decreased chance of respiratory depression and death. 
 To date, the mechanisms involved with the development of opioid analgesic 
tolerance are a point of controversy. Past research on the development of tolerance (non-
specific to acute or chronic pain) suggests that overexposure to MOP agonists (e.g. 
fentanyl) initiate phosphorylation of the receptor via GPCR kinases, resulting in the 
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recruitment of the regulating molecule β-arrestin (Figure 1) (Lohse et al. 1989). Once the 
β-arrestin binds to the MOP, the G-protein agonist uncouples itself from the GPCR, 
causing the receptor desensitization. Additionally, β-arrestin can cause the entire GPCR 
to become internalized, completely inhibiting activation and signaling of the MOP 
(Figure 1). This result was confirmed by a β-arrestin knockout experiment in mice that 
noted a lack of opioid receptor desensitization when opioids were administered 
chronically (Bohn et al. 1999). Therefore, MOPs in β-arrestin knockout mice were able to 
bind agonists and signal normally, producing an analgesic response similar to that of 
mice without opioid induced tolerance. Thus, desensitization and internalization of MOPs 
from repeated use reduces the number of opioid receptors that are available to signal and 
produce analgesic effects. Besides desensitization and internalization of MOPs, the body 
can also decrease the production of endorphins, endomorphins, and enkephalins – 
endogenous opioids produced by the body in response to pain – when trying to combat 
the increased levels of opioids. This ultimately leads to the continued sensation of pain 
because a decreased amount of endogenous opioids are released from the pituitary gland 
and hypothalamus (Kurita et al. 2011).  
While previous in vitro studies have suggested opioid tolerance is caused by the 
down regulation of pathways involved with MOPs (Harrison et al. 2010), current research 
does not show that down-regulation of MOPs consistently occurs for every agonist (e.g., 
morphine vs. fentanyl) (Dang and Christie 2012). Additionally, a recent study analyzing 
the inhibition of β-arrestin recruitment in mice found that inhibition of MOP 
phosphorylation alone does not completely block the development of opioid tolerance 
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and can potentially worsen opioid side effects (Kliewer et al. 2019). Thus, it is important 
to study other pathways that may be involved with the development of morphine 
tolerance. 
Opioids and the Treatment of Neuropathic Chronic Pain 
There are many studies analyzing the acute effects of opioids on treating chronic 
pain. However, not much is known regarding how opioid signaling changes under 
neuropathic chronic pain. A 2016 study found 18.8% of patients suffering from 
neuropathy were receiving long-term opioid treatment (Hoffman et al. 2017). With the 
only FDA-labeled opioid for neuropathy treatment being tapentadol, most opioids are 
kept as a third-line treatment due to the potential for adverse risks (Colloca et al. 2017; 
Vadivelu et al. 2015). Previous reports have suggested that the use of opioids for treating 
chronic neuropathic pain should be discouraged clinically as they are often ineffective at 
low doses, increasing the risk for tolerance and addiction as the dosages escalate 
(Rowbotham et al. 2003). As stated previously, current research suggests opioid 
resistance to chronic neuropathic pain treatment may be more relative than absolute, with 
the neuropathic pain mechanisms involved with reducing opioid responsiveness not 
causing inherent resistance. Additionally, most short-term studies on the use of opioids 
for chronic neuropathic pain produce varied results, with only about 50% of those in the 
studies indicating opioids had more of an analgesic effect than the placebo (McNicol ED 
et al. 2013). Thus, the use of opioids for chronic neuropathic pain management continues 
to be an area of great discussion due to the variability in treatment outcomes given the 
complexity of factors that can affect neuropathic pain. 
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To study the treatment of neuropathic pain in rodents, one common animal model 
involves the ligation of the lumbar segmental spinal nerve usually at the ventral ramus at 
either the L4, L5, or L6 (Ho Kim and Mo Chung 1992). Once ligated, axonal degradation 
begins to occur, leading to the development of spontaneous pain, cold allodynia, and 
mechanical allodynia (Luo et al. 2004). Previous studies have successfully used the 
rodent spinal nerve ligation model to study the effects of morphine on neuropathic pain, 
with a wide range of systemic doses of morphine (Suzuki, Chapman, and Dickenson 
1999). After the sciatic nerve is ligated, there are many different maladaptive changes 
that can occur at the site of ligation that cause chronic pain and peripheral sensitivity 
including the initial inflammation that occurs after ligation, death of part of the nerve that 
no longer signals to the spinal cord, the development of neuromas, the spread of sodium 
channels, and an increase in calcium channels (Znaor et al. 2007). The inflammation that 
occurs after the injury and during the healing process (creation of neuroma) causes 
hyperexcitability as byproducts during the repair process can sensitize and excite 
nociceptors. The part of the nerve that is dying also increases hyperexcitability as the 
branches of the sciatic nerve that are still attached (L5 and L6) can signal with and sense 
the death of the L4 portion. Additionally, at the site of the ligation it is hypothesized that 
sodium channels begin to cluster, and the expression of calcium channels increases. 
While these changes in expression levels can alone lead to hyperactivity and central 
sensitization, the addition of morphine tolerance can simulate what may happen to 
chronic pain patients taking opioids for pain management. Additionally, the uninjured 
side of the neuropathic pain rodents are not comparable to the naïve rodents as the 
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inflammation that occurs after the injury is not localized to the site of injury and can be 
systemic, also affecting any uninjured nerves and higher order brain centers. A past 
report has shown that nerve ligation in mice can induce systemic hypersensitivity in 
uninjured peripheral afferent fibers (Smith, O’Hara, and Stucky 2013). With the 
effectiveness of opioids on neuropathic pain still up for debate, the spinal nerve ligation 
model is an important tool that allows for analysis of the molecular mechanisms involved 
with neuropathic pain and opioid treatment.  
KATP Channels and Opioids  
Potassium channels are one of the most abundant and widely distributed ion 
channels found in most cell types (Littleton and Ganetzky 2000). Divided into four major 
classes—calcium-activated, inwardly rectifying, tandem pore domain, and voltage-
gated— the main function of potassium channels is to regulate action potentials by 
modulating the cell resting potential. With potassium channels aiding in the regulation of 
action potentials, they make an interesting potential target for the treatment of pain. One 
class of potassium channels, the inwardly rectifying potassium channels (specifically 
Kir3.x), have been previously studied for their effects on opioid related analgesia and 
respiratory depression (Kovoor, Henry, and Chavkin 1995; Montandon et al. 2016; Nagi 
and Pineyro 2014; Seth et al. 2010).  
Within the inwardly rectifying potassium channel class, the ATP-sensitive 
potassium channels (Kir6.x) poses as another interesting pain treatment target. The 
subunits that compose the hetero-octameric protein structure of the KATP channel include 
the regulatory sulfonylurea receptor-1 (SUR1) or SUR2 subunits and the pore-forming 
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Kir6.1 or Kir6.2 subunits. KATP channels are located in smooth muscle, pancreas, brain, 
dorsal root ganglia, and superficial dorsal horn of the spinal cord (Fotinou et al. 2013; 
Gerzanich et al. 2019; Zoga et al. 2010). Interestingly, previous studies have reported a 
decrease in KATP expression in dorsal root ganglia after a painful nerve injury 
(Sarantopoulos et al. 2003). These findings suggest that the current created by the 
opening of KATP channels in the primary afferent neurons is decreased after nerve injury 
and contributes to chronic pain. Additionally, previous reports have found NO (part of 
the PI3K/AKT intracellular signaling pathway) induced KATP channel activation in the 
dorsal root ganglia weeks after spinal nerve ligation surgeries in rats (Kawano et al. 
2009).  The KATP channel activation by NO suggests the potential involvement of the 
PI3K/AKT intracellular signaling pathway in KATP channel activation, and may be a point 
of interest during morphine tolerance and neuropathic pain treatment because of KATP 
channel’s ability to hyperpolarize neurons and cause analgesia (Cao et al. 2016; Zhu et al. 
2015; Figure 3).  
Opioids and the PI3K/AKT Pathway  
While the activation of the KATP channels to produce analgesic effects have been 
previously reported, many intracellular signaling pathways leading up to KATP channel 
activation are still largely unknown (Cao et al. 2016). One suggested pathway involved 
with the opioid signaling cascade that leads to KATP channel activation is the PI3K/AKT 
pathway. Traditionally used by oncology researchers for its involvement with cancer 
progression, the PI3K/AKT signaling cascade contains neuronal nitric oxide synthase 
(nNOS), nitric oxide (NO), guanylate cyclase (GC), cyclic guanosine monophosphate 
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(cGMP), and KATP channels. Besides inhibiting calcium channels, the Gβγ subunit of the 
MOPs can also stimulate PI3K (New et al. 2007). This stimulation causes the 
phosphorylation of phosphatidylinositol bisphosphate (PIP2), leading to the formation of 
phosphatidylinositol trisphosphate (PIP3) and activation of phosphoinositide-dependent 
kinase-1 (PDK1) (Gerson et al. 2017). Phosphatase and tensin homolog (PTEN), a 
negative regulator of PI3K, may also be involved with opioid induced tolerance and has 
been shown to be upregulated during morphine tolerance (Yang et al. 2008). Once PDK1 
is activated, it can phosphorylate protein kinase B (AKT) and lead to the activation of the 
neuronal signaling molecule nitric oxide synthase (nNOS) which stimulates the creation 
of nitric oxide (NO). NO is then free to activate guanylyl cyclase (GC), which 
synthesizes cyclic guanosine monophosphate (cGMP) from guanosine triphosphate 
(GTP). Finally, cGMP activates protein kinase G (PKG), leading to the activation of 
Kir6.x and analgesia either directly or through stimulation by the 
ROS/calmodulin/CaMKII signaling cascade (Cao et al. 2016; Chai, Zhang, and Lin 2011; 
Ding et al. 2017). Jun amino-terminal kinases (JNK), a downstream target of the 
PI3K/AKT pathway, may also be involved with morphine tolerance and has been shown 
to be upregulated during morphine tolerance (Fan et al. 2003). 
A study that utilized the KATP channel opener chromakalim in conjunction with 
morphine found that the subsequent opening of the KATP channels led to the attenuation 
of morphine tolerance in mice (Cao et al. 2016). Since KATP channels can be activated by 
the PI3K/AKT downstream effector cGMP, and because KATP channel activation has 
been found to attenuate the development of morphine tolerance, the PI3K/AKT 
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intracellular signaling pathway is a promising target for reducing opioid induced 
tolerance in patients. However, further research into the PI3K/AKT pathway, including 
analysis of the downstream targets during both morphine tolerance and morphine 
tolerance with neuropathic pain, needs to be assessed. 
 Because the PI3K/AKT pathway is involved with many other cellular processes, 
targeting opioid signaling requires identifying the specific isoforms present in the 
nervous system. Currently, there are three known PI3K isoforms: PI3Kγ (PIK3cg), 
PI3Kα, PI3Kβ (Cunha et al. 2010). The level in which these variants are involved with 
opioid receptor signaling was first documented by Cunha et al, which found PI3Kγ to be 
more greatly expressed in the nervous system (brain) and immune system (bone marrow 
and lymph nodes) (Cunha et al. 2010). When analyzing PI3Kγ’s role in analgesia, Cunha 
et al. used both selective PI3Kγ inhibitors and generalized PI3K inhibitors on mice to 
record their responses to a pain stimulus. This study found that mice given the PI3K 
inhibitors and then subsequently tested with a force transducer to evoke hind-paw flexion 
had a slower response time to pain than mice given saline, but not as slow as mice given 
morphine. These findings suggest the PI3K/AKT signaling cascade may play a crucial 
role in enhancing the pain-relieving effects of morphine and targeting this MOP signaling 
pathway with PI3K inhibitors may help to produce analgesic effects while bypassing 
most of the risks for addiction and tolerance. Although the findings by Cunha et al. 2010 
showed PI3K’s involvement with analgesia, their research was limited to just PI3Kγ. 
Therefore, the downstream signaling molecules of the PI3K/AKT pathway require further 
research. 
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The PI3K/AKT pathway is predicted to induce analgesia through the eventual 
activation of inwardly rectifying potassium channels (Kir6.x) (Figure 4; Cunha et al. 
2010). Research presented here sought to determine if opioid induced tolerance is linked 
to a decreased gene expression activity in the PI3K/AKT intracellular signaling pathway 
(Figure 3 and 4b).  
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Figure 3. PI3K/AKT Signaling Pathway. Positive effects are indicated by (+), while 
negative effects are indicated by (-). Arrows represent activation events, T lines represent 
inhibition, and dotted arrows represent further pathway interactions (protein kinase G). 
List of abbreviations:  G-protein coupled receptor (GPCR; mu opioid receptor), inhibitory 
G-protein (Gi), βγ G-protein subunit (Gβγ), phosphoinositide 3-kinase catalytic subunit 
gamma (PIK3cg), phosphatidylinositol bisphosphate (PIP2), phosphatidylinositol 
triphosphate (PIP3), phosphatase and tensin homolog (PTEN), phosphoinositide-
dependent kinase-1 (PDK1), protein kinase B (AKT), neuronal nitric oxide synthase 
(nNOS), nitric oxide (NO), guanylate cyclase (GC), guanosine triphosphate (GTP), cyclic 
guanosine monophosphate (cGMP), jun amino-terminal kinases (JNK), inwardly 
rectifying potassium channels (Kir6.x). 
 
 Kir6.x 
PIK3cg 
JNK 
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Figure 4. Hypothesized PI3K/AKT signaling mechanism of analgesia and opioid 
tolerance induced by KATP channels in the nervous system. a, Activation of mu-opioid 
receptors (MOPs) and KATP channels by opioid agonists (triangles) decrease neuron/nerve 
fiber excitability through the proposed downstream signaling of the PI3K/AKT pathway. 
b, During opioid induced tolerance (OIT) and opioid induced hyperalgesia (OIH), there is 
a proposed loss of MOR downstream signaling. A decrease in the expression of the 
PI3K/AKT pathway could contribute to OIT and OIH by inhibiting KATP channel activity 
and/or initiating a decrease in KATP channel expression. Downward arrows indicate a 
decrease in gene expression/activity, while upward arrows indicate an increase in 
expression/activity. List of abbreviations:  Phosphatase and tensin homolog (PTEN), 
phosphoinositide 3-kinase (PI3K), protein kinase B (AKT), neuronal nitric oxide 
synthase (nNOS), nitric oxide (NO) guanylate cyclase (GC), cyclic guanosine 
monophosphate (cGMP), protein kinase G (PKG), jun amino-terminal kinases (JNK).  
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Overall, the specific signaling molecule variants that are involved with MOP 
signaling, as well as their gene expression levels in various areas of the central and 
peripheral nervous system, are still unknown. The importance of this project is to fill in 
the knowledge gap regarding how the PI3K/AKT pathway changes during morphine 
tolerance with and without chronic pain, as prior work has focused either on chronic pain 
or morphine tolerance separately. Therefore, there are three questions that can be 
addressed regarding the PI3K/AKT pathway and morphine tolerance: (1) Does gene 
expression within the PI3K/AKT pathway decrease in mice that are morphine tolerant? 
(2) Does gene expression within the PI3K/AKT pathway decrease in mice with 
neuropathic pain (SNL model) that are also morphine tolerant? (3) Will inhibiting 
signaling molecules of the PI3K/AKT pathway in mice that are given morphine alter the 
severity of morphine tolerance development?  
The goal of the first question is to determine whether gene expression of the 
PI3K/AKT pathway is reduced in mice that are tolerant to morphine. To accomplish this, 
a group of mice injected with saline are compared with a group of mice injected with 
morphine twice daily by analyzing gene expression within each group. Mice were used in 
this study as their nociceptive pathways have been found to be comparable to that of 
humans (Abdelhamid et al. 1991; Babbini and Davis 1972; Kolesnikov et al. 2006; 
Shimomura et al. 2009). We will also determine whether cGMP is involved in morphine 
tolerance through analysis of cGMP nucleotide levels. 
The goal of the second experiment is to study the effects of chronic neuropathic 
pain on the gene expression levels of the PI3K/AKT pathway in morphine tolerant mice. 
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The use of both morphine tolerant and morphine tolerant mice with spinal nerve ligations 
allows us to analyze the PI3K/AKT pathway gene expression effects of chronic pain on 
the development on morphine tolerance. We will have also determined whether cGMP is 
involved in morphine tolerance through analysis of cGMP nucleotide levels in MT+SNL 
mice. 
The goal of third experiment is to study the effects of various inhibitors of the 
PI3K/AKT pathway on the development of morphine tolerance. The inhibitors are 
thalidomide (PI3K/AKT/NOS inhibitor), SP600125 (JNK inhibitor), and quercetin 
(PI3Kcg inhibitor).  
At the end of all three of these experiments we will have analyzed how the 
PI3K/AKT intracellular pathway changes during morphine tolerance. In addition, we will 
have determined whether pharmacologically altering the PI3K/AKT pathway promotes or 
attenuates the development of tolerance. 
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Materials and Methods 
Animals 
The University of Minnesota Institutional Animal Care and Use Committee 
approved all animal procedures. For all experiments, adult C57Bl/6 WT male mice were 
acquired from Charles River Laboratories (Raleigh, NC) at 6 weeks old. The mice were 
split into two different experimental groups: mice given saline or morphine, and mice 
with a spinal nerve ligation (SNL, below) given a vehicle (20% DMSO, 5% Tween 20, 
75% saline) or morphine, with or without a PI3K/AKT pathway inhibitor. At the end of 
each experiment, mice were euthanized with 5% isoflurane and decapitated before the 
brain, brainstem, spinal cord, dorsal root ganglia, sciatic nerve, and trigeminal ganglia 
were snap frozen in liquid nitrogen and stored at -80°C.  
Spinal Nerve Ligation  
To model the effects of neuropathic pain in a mouse model, spinal nerve ligation 
was performed (Masuda et al. 2017). Mice were anesthetized with 3% isoflurane (1.5% 
post-anesthetization) in an O2 carrier. The area above the L3 to S3 vertebrae was shaved 
and cleaned with povidone iodine (Betadine; item no.: 1413, Dynarex, Orangeburg, NY). 
An incision into the skin and fascia was made above the L5 to S1 vertebra. To expose and 
transect the left L4 spinal nerve, the paravertebral musculature was removed from the 
vertebral transverse processes, along with a portion of the L5 transverse process (Figure 
5). The incision was closed with two layers of 4-0 vicryl sutures (item no.: J304H, 
Ethicon, Bridgewater, NJ) and cleaned with Betadine. The right spinal nerves were left 
intact (contralateral). The mice were given 14 days to heal before behavioral testing.  
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Figure 5: Spinal Nerve Ligation Diagram. The sciatic nerve was ligated (jagged lines) 
at the L4. 
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Drug Delivery and Behavior Testing  
All mice followed the same drug injection and behavior testing schedule (Figure 
6). The saline treated mice (7-8 weeks old) were given subcutaneous 100 µL saline (item 
no.: V1 501224, Vet One, Boise, ID) injections twice a day for a total of five days and 
were used as controls for morphine tolerant mice with SNL (MT+SNL;10 weeks old) and 
without SNL (MT; 7-8 weeks old). To induce morphine tolerance, mice were given 
subcutaneous 15 mg/kg morphine injections twice a day for a total of five days. 
MT+SNL Mice given intraperitoneal 100 µL injections of 20% DMSO, 5% Tween 20, 
75% saline twice a day for a total of five days were used as controls for MT+SNL mice 
that were utilized for PI3K/AKT pathway inhibitor examination. PI3K/AKT pathway 
inhibitors of either quercetin (item no.: SC-206089A, Santa Cruz Biotechnology Dallas, 
TX; PIK3cg inhibitor; 60mg/kg; 100% saline; 30 mins prior to morphine inj.), 
thalidomide (item no.: J60271, Alfa Aesar, Ward Hill, MA; PI3K/AKT/nNOS inhibitor; 
100mg/kg; 10% DMSO, 90% saline; 15 mins prior to morphine inj.), or SP600125 (item 
no.: S-7979, LC Laboratories, Woburn, MA; JNK inhibitor; 10mg/kg; 20% DMSO, 5% 
Tween 20, 75% saline; 30 mins prior to morphine inj.) before being given subcutaneous 
15 mg/kg morphine injections. This process was repeated twice a day for a total of five 
days.  
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Figure 6. Experiment timeline of behavior testing including drug injections. Mice 
were injected with their respective drugs at ~0800 and ~1800 hours. Behavior testing 
(light grey; thermal radiant heat withdrawal latency) was recorded on days 1, 3, and 5. 
For all experiment groups, tissues were harvested on day 6.  
 
 
 
 
 
 
 
 
 
 
 
 
(0800 hours) 
(1800 hours) 
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Thermal Paw Withdrawal Latency 
All mice were acclimated to the testing apparatus (individual acrylic containers on 
a glass bed heated to 30oC) at least 3 days prior to the start of the experiments. Thermal 
paw withdrawal latency (TPWL) (modified Hargreaves’ Method) in seconds was 
measured for each group before (baseline; collected five times for each trial) and 0, 30, 
and 60 minutes post final injection(s) using a thermal plantar analgesia meter (item no.: 
390G, IITC, Woodland Hills, CA) (Banik and Kabadi 2013). A radiant heat source was 
placed under the hindpaws of the mice that would increase in temperature until the mice 
withdrew their hindpaws. The time (latency in seconds) it took for the mice to move their 
hindpaws away from the radiant heat source was recorded. Measurements were taken on 
days 0, 3, and 5 for MT, MT+SNL mice, and MT+SNL+inhibitor mice. 
RNA Extraction  
Total RNA was isolated from the saline, MT, and MT+SNL mice (8-10 weeks 
old) brainstem (BS), spinal cord (SC), dorsal root ganglia (DRG), and sciatic nerves (SN) 
on day 6 (post testing) using RNeasy Micro kit (item no.: 74106, Qiagen, Valencia, CA). 
All tissues were individually homogenized in 1 mL Tri Reagent (item no.: TR118, 
Molecular Research Center Inc., Cincinnati, OH) and let stand for 5 minutes in 0.1 mL 
Bromo 3-chloropropane (item no.: B9673, Sigma Aldrich, St. Louis, MO) before being 
centrifuged at 12,000 rcf for 15 minutes at 4°C. The aqueous phase of each sample was 
removed and added to one volume of 70% ethanol. After vortexing, each sample was 
placed into a RNeasy Mini spin column (item no.: 1011708, Qiagen, Valencia CA) and 
centrifuged for 30 seconds at 8,000 rcf. Once the flow-through was discarded, 350 μL 
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buffer RW1 (item no.: 1015763, Qiagen, Valencia CA) was added and subsequently 
centrifuged at the same settings as prior to wash the membrane. A solution of 10 μL 
DNase I (item no.: EN0521, ThermoFisher Scientific, Waltham, MA) to 70 μL Buffer 
RDD (item no.: 160027653, Qiagen, Valencia CA) was added to the spin column 
membrane and let stand for 30 minutes before being washed with 500 μL buffer RPE 
(item no.: 1019966, Qiagen, Valencia CA) twice (8,000 rcf; 30 seconds for the first wash, 
2 minutes for the second wash). The remain RNA on the spin column membrane was 
collected by adding 35 μL RNase-free water centrifuging for 1 minute at 8,000 rcf. RNA 
concentrations for every sample were read using a Nanodrop 1000 (item no.: E112352, 
Nanodrop Technologies, Wilmington, DE) and assessed for purity by requiring an 
A260/A280 ratio of 1.8 to 2.2 before being stored at -80˚C.  
cDNA 
A cDNA library was created for each RNA sample using Omniscript RT (item 
no.: 205113, Qiagen, Valencia CA). The RNA samples were diluted to 50 ng to a final 
volume of 10.75 μL using RNase free water. A reaction mix composed random nonamers 
(4 μL; item no.: 16107289, IDT, Coralville, IA), RNase out (1 μL item no.: 2001863, 
Invitrogen, Waltham, MA), RT O (1 μL; item no.: 160029551, Qiagen, Valencia CA), 
dNTP (2 μL; item no.: 160037073, Qiagen, Valencia CA), and buffer RT (2 μL; item no.: 
160038077, Qiagen, Valencia CA) was added to every RNA sample (9.25 μL per sample) 
in 200 μL PCR tubes. The samples were run in a GeneAmp® PCR System 9700 (item 
no.; N8050200, Applied Biosystems, Waltham, MA) at 37˚C for 60 minutes, 93˚C for 3 
minutes, and held at 4˚C before being stored at -80˚C. A RT negative control was also 
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created for each sample using the same procedure, except the RT O was replaced with 1 
μL of RNase free water. The RT negative samples were run for Rn18s (ribosomal RNA 
gene) as an internal control. 
RT-qPCR  
1. Standards 
The standard curve was created using a reference samples that were created using 
genomic DNA (0.95 μL), Amplitaq Gold™ (item no.: 4398876, ThermoFisher Scientific, 
Waltham, MA), the forward and reverse primers for the gene of interest (2 μL each), and 
RNase free water. The samples were run on a GeneAmp® PCR System 9700 for 5 
minutes at 95˚C, a 35x repeated cycle composed of 30 seconds at 95˚C, 60 seconds at 
60˚C, and 45 seconds at 72˚C before a final 7 minutes at 72˚C. The products were then 
checked using an Agarose gel (item no.:20-101QD, Apex, El Cajon, CA) with a 100 bp 
ladder. After confirmation, the products were then cleaned using QIAquick PCR 
purification kit (item no.: 28104, Qiagen, Valencia, CA). The standards were then diluted 
to a base 5e9 copies/ μL (200 μL total), before being serial diluted down to 5e2 copies/ 
μL. To get the copies/ μL in every sample, a nanodrop was used to record the ng/ μL and 
converted to μg/ μL before using the equation: 
𝐶𝑜𝑝𝑖𝑒𝑠
𝜇𝐿
 =
𝜇𝑔
𝜇𝐿 ∗ 6.022 ∗ 10
17
𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑤𝑒𝑖𝑔ℎ𝑡
 
To find the approximate molecular weight of dsDNA, the following equation was used: 
𝑀𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑤𝑒𝑖𝑔ℎ𝑡 = (𝑏𝑎𝑠𝑒 𝑝𝑎𝑖𝑟𝑠 ∗ 607.4)  +  157.9 
2. Samples 
For every sample of cDNA, a master mix composed of SYBR® green 1 (5 μL; item 
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no.:27584120, Roche Diagnostics, Indianapolis, IN), forward and reverse primers (0.5 μL 
each) for each specific gene of interest (Table 1; IDT, Coralville, IA), and RNase free 
water was used. The real-time PCR protocol: heat activation of polymerase at 95°C for 
10 minutes, followed by 40 cycles of: 95°C for 20 seconds, 65°C for 20 seconds and 
72°C for 20 seconds. Readings were carried out on a Roche LightCycler® 480 System 
(Roche Diagnostics, Indianapolis, IN), and compared against a standard curve created 
from genomic DNA. The qPCR data was standardized to Rn18s prior to analysis. A 
negative RT control was run for every RT negative cDNA sample using Rn18s and the 
same real-time PCR protocol. 
Primer Selection  
Primers were created using Primer-BLAST (NCBI, Bethesda, MD) and selected 
for mus musculus (Ye et al. 2012). Ideal primer conditions were considered to be less 
than 200 bp long, have a melting point around 60°C, a GC content around 40-60%, and 
span an exon-exon junction. Splice variants of genes were also analyzed and denoted 
with a “v”. 
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Table 1. qPCR Primers 
Forward and reverse qPCR primers for genes in the PI3K/AKT intracellular signaling 
pathway. The “v” indicates splice variants. 
 
                       R
n
1
8
s 
K
cn
j1
1
 v2
 
K
cn
j1
1
 v1
 
K
cn
j8
 
A
b
cc9
 
A
b
cc8
 
O
p
rm
1
 
Jn
k3
 
n
N
o
s1
 
P
ten
 
P
ik3
cg
 v3
 
P
ik3
cg
 v2
 
P
ik3
cg
 v1
 
A
kt3
 
A
kt2
 
A
kt1
 
G
e
n
e 
   
R
n
1
8
s 
K
cn
j1
1
 
K
cn
j1
1
 
K
cn
j8
 
A
b
cc9
 
A
b
cc8
 
O
p
rm
1
 
M
a
p
k1
0
 
N
o
s1
 
P
ten
 
P
ik3
cg
 
P
ik3
cg
 
P
ik3
cg
 
A
kt3
 
A
kt2
 
A
kt1
 
G
e
n
e
 S
y
m
b
o
l 
   
1
9
7
9
1
 
1
6
5
1
4
 
1
6
5
1
4
 
1
6
5
2
3
 
2
0
9
2
8
 
2
0
9
2
7
 
1
8
3
9
0
 
2
6
4
1
4
 
 
1
8
1
2
5
 
1
9
2
1
1
 
3
0
9
5
5
 
3
0
9
5
5
 
3
0
9
5
5
 
2
3
7
9
7
 
1
1
6
5
2
 
1
1
6
5
1
 
N
C
B
I G
e
n
e
 ID
 
   
  C
G
C
 C
G
C
 T
A
G
 A
G
G
 T
G
A
 A
A
T
 T
C
T
 T
 
 A
C
C
 A
C
G
 T
C
A
 T
C
G
 A
C
T
 C
C
A
 A
C
 
C
G
C
 C
C
A
 C
A
A
 G
A
A
 C
A
T
 T
C
G
 A
G
 
G
G
C
 A
C
C
 A
T
G
 G
A
G
 A
A
G
 A
G
T
 G
G
 
T
G
T
 A
G
G
 C
C
A
 A
G
T
 G
G
G
 T
T
G
 T
G
 
G
A
T
 G
G
G
 G
T
G
 A
C
A
 G
A
A
 T
C
C
 C
G
 
C
A
C
 C
C
C
 T
C
C
 A
C
G
 G
C
T
 A
A
T
 A
C
 
A
G
G
 T
G
G
 A
C
A
 A
C
C
 A
G
T
 T
C
T
 A
C
A
 
A
G
C
 A
T
G
 A
C
T
 T
C
C
 G
A
G
 T
G
T
 G
G
 
T
C
T
 G
C
C
 A
T
C
 T
C
T
 C
T
C
 C
T
C
 C
T
T
 
A
T
G
 A
T
C
 C
T
C
 C
T
C
 C
G
C
 A
T
C
 A
C
 
C
A
A
 A
G
C
 T
A
C
 T
T
A
 G
T
C
 C
C
A
 G
C
C
 A
T
 
C
A
T
 C
C
A
 C
A
A
 A
G
T
 T
C
C
 G
T
C
 C
A
G
 
G
G
A
 G
G
G
 C
C
A
 G
A
T
 G
A
T
 G
C
A
 A
A
 
T
C
C
 T
C
C
 C
C
C
 T
G
C
 T
C
T
 T
A
A
 C
T
 
A
T
G
 A
A
C
 G
A
C
 G
T
A
 G
C
C
 A
T
T
 G
T
G
 
F
o
rw
a
rd
 P
rim
e
r 
   
  C
A
G
 T
C
G
 G
C
A
 T
C
G
 T
T
T
 A
T
G
 G
T
C
 
 T
G
G
 T
T
T
 C
T
A
 C
C
A
 C
G
C
 C
T
T
 C
C
 
G
C
A
 G
A
G
 T
G
T
 G
T
G
 G
C
C
 A
T
T
 T
G
 
C
A
A
 A
A
C
 C
G
T
 G
A
T
 G
G
C
 C
A
G
 A
G
 
T
C
T
 G
C
T
 T
C
G
 G
G
T
 T
G
C
 T
T
C
 A
A
 
G
G
C
 G
T
G
 G
T
C
 G
T
A
 G
A
A
 C
T
T
 G
A
 
C
C
A
 C
A
A
 A
C
C
 C
T
G
 A
C
A
 G
C
A
 A
C
 
G
C
A
 C
A
G
 A
C
T
 A
T
T
 C
C
C
 T
G
A
 G
C
C
 
T
G
C
 C
G
T
 C
G
T
 C
G
T
 C
A
T
 A
C
T
 T
T
 
T
T
C
 T
G
C
 A
G
G
 A
A
A
 T
C
C
 C
A
T
 A
G
C
 A
A
 
G
G
T
 G
G
G
 C
A
G
 T
A
C
 G
A
A
 C
T
C
 A
A
 
A
C
C
 A
C
C
 G
G
T
 T
G
T
 T
C
A
 T
A
G
 T
T
C
 T
 
G
C
G
 G
A
G
 G
T
T
 G
T
C
 C
T
C
 T
C
T
 T
A
G
 
T
G
C
 C
G
T
 C
G
T
 C
G
T
 C
A
T
 A
C
T
 T
T
 
C
A
C
 A
C
G
 C
T
G
 T
C
A
 C
C
T
 A
G
C
 T
T
 
T
T
G
 T
A
G
 C
C
A
 A
T
A
 A
A
G
 G
T
G
 C
C
A
 T
 
R
e
ve
rse P
rim
er 
32 
 
ELISA 
cGMP levels in MT mice brainstem, spinal cord, dorsal root ganglia, and sciatic 
nerve were measured using an ELISA kit (Item No.: 581021, Cayman Chemical 
Company, Ann-Arbor, MI). Manufacturer protocol was utilized and scaled to 
accommodate tissues <0.05 g. Tissues were homogenized in 10 volumes (mL of 
solution/gram of tissue) of 5% trichloroacetic acid (TCA; 200 µL minimum) in water 
before being centrifuged at 1,500 rcf for 10 minutes. The supernatant of every sample 
was then washed with 5 volumes of water-saturated diethyl ether 3 times to extract the 
TCA from the sample. Residual water-saturated diethyl ether was removed by heating the 
samples to 70°C for five minutes before being diluted 1:5 with ELISA buffer supplied in 
the kit. Standards were prepped by serial diluting standard A found in the kit. Both the 
samples and standards were acetylated by adding 100 µL of 4 M KOH and 25 µL Acetic 
Anhydride, vortexing for 15 seconds, and then adding an additional 25 µL of 4 M KOH. 
50 µL of each sample and standard was plated with corresponding amounts of cGMP 
AChE Tracer and ELISA antiserum. Each plate was incubated for 18 hours at 4°C. After 
incubation, each well was washed 5 times with the supplied Wash buffer before 200 µL 
of Ellman’s Reagent was added to each well. Before developing the plates on an orbital 
shaker for 2 hours, 5 µL of cGMP AChE Tracer had to be added to the total activity 
wells. Once developed, the plates were read in a Biotech Synergy 2 (BioTek Instruments, 
Inc., Winooski, VT) at 410 nm. 
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Data Analysis 
1. Behavioral Experiments 
Behavioral experiments involving the saline and MT mice without SNL were 
analyzed using an ANOVA with a Dunnett post-hoc test comparing the MT mice to the 
saline mice. The F-test reported are comparing the treatments (saline and MT). An 
ANOVA was also used for the MT+SNL mice to compare ipsilateral (‘ipsi’) and 
contralateral (‘contra’) hindpaw measurements to saline treated mice. The F-test reported 
are comparing the treatments (MT+SNLipsi and MT+SNLcontra). For the MT+SNL mice 
given PI3K/AKT pathway inhibitors, repeated measures ANOVA using a Dunnett post-
hoc test was utilized for analyses to compare the MT+SNL vehicle mice to the MT+SNL 
inhibitor mice for both ipsi and contra. The F-test reported are comparing the treatments 
(vehicle, thalidomide, quercetin, SP600125). The standard error of the mean (SEM) was 
reported for all statistics as it incorporates stranded deviation and sample size, and is 
commonly used in this field of study. Statistics were completed using Prism 6 (GraphPad 
Software, La Jolla, CA). 
2. qPCR 
A standard curve using Ct values vs log-transformed concentration from known 
standard concentrations (5e2 to 5e7) was used to convert sample Ct values to 
concentrations. The sample number of copies were then standardized to Rn18s number of 
copies. An ANOVA with a Dunnett’s multiple comparisons test was used to compare 
mice subcutaneously injected with saline to MT and MT+SNL (ipsi and contra) mice. For 
the comparison of treatments back to saline, each individual sample was compared to the 
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mean value of saline before being averaged by treatment. The F-tests reported for qPCR 
are comparing treatments (saline, MT, MT+SNLipsi, and MT+SNLcontra). All statistics 
were completed using Prism 6 (GraphPad Software, La Jolla, CA). 
3. cGMP ELISA 
For the cGMP ELISA data, the average non-specific binding (NSB) wells were 
subtracted from the maximum binding (B0) wells to get the corrected maximum binding. 
The standards were linearized as  
ln((B/B0)/(1 - B/B0)) 
for every standard and sample (B). The concentration (C; pmol/mL) of every sample was 
found by using the following equation: 
C = EXP((LB - Y)/S)*D 
where LB is the linearized sample, Y is the y-intercept of the linearized standards, S is 
the slope of the linearized standards, and D is the dilution factor used. An ANOVA with a 
Dunnett’s multiple comparisons test was used to compare mice subcutaneously injected 
with saline to MT and MT+SNL (ipsi and contra) mice. F-tests reported are comparing 
treatments (saline, MT, MT+SNLipsi, and MT+SNLcontra). All statistics were completed 
using Prism 6 (GraphPad Software, La Jolla, CA). 
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Results 
1. Morphine Tolerance (Question #1) 
Thermal Paw Latency in Morphine Tolerant Mice 
To verify if mice developed morphine tolerance, TPWL was measured every other 
day for 5 days. Mice were injected with either saline or 15 mg/kg morphine in saline 
twice daily. 15mg/kg was chosen as a middle ground dosage as previous studies having 
used anywhere from 5-100 mg/kg to induce morphine tolerance (Abdelhamid et al. 1991; 
Babbini and Davis 1972; Kolesnikov et al. 2006; Shimomura et al. 2009). Saline injected 
mice were chosen instead of mice given acute morphine as there would not be recordable 
gene expression differences for acute morphine mice on day 1. An ANOVA with a 
Dunnett post-hoc test was utilized to compare the MT mice to the saline mice for the 
pretest, day 1, day 3, and day 5 (F1, 407=43.22; P<0.0001). Saline and morphine tolerant 
(MT) mice had the same TPWL prior to any drug injections (pre-test; p>0.9999) (Figure 
7). Behavior testing for saline and MT mice on day 1 were significantly different from 
each other 30 minutes post injections (p<0.0001). On day 3 and 5 of behavior testing, 
both groups had no significant differences in TPWL 30 minutes post injection 
(p>0.9999). The lack of a significant difference between saline- and morphine-treated 
mice on days 3 and 5 indicates the development of opioid induced tolerance by day 3. 
Therefore, the development of opioid induced tolerance insured the mice were morphine 
tolerant before being harvested for gene expression analysis to analyze question 1.  
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Figure 7. MT developed by day 3 and was sustained through day 5. TPWL thresholds 
for morphine tolerant- (15mg/kg, x2 day, 5 days; squares) and saline-treated (100 µL 
saline, x2 day, 5 days; circles) mice 30 mins post-injection. Data are expressed as mean ± 
SEM. An ANOVA with a Dunnett post-hoc test comparing the MT mice to the saline 
mice was used (n=14) for days 1 (including pre-test), 3, and 5; ****p<0.0001. 
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Gene Expression  
To analyze question 1, gene expression was assessed for 15 different genes in the 
brainstem (BS), spinal cord (SC), dorsal root ganglia (DRG), and sciatic nerve (SN) 
using qPCR (Figures 8-11, Tables 2-5). Each gene (including isoforms and splice 
variants) were chosen because they were all potential downstream targets of the MOP 
in the PI3K/AKT intracellular signaling pathway. Pik3cg (splice variants 1-3) are 
important cellular signal modulators and are class 1 catalytic polypeptides, Akt1 
inhibits apoptosis, Akt2 is involved with insulin signaling, Akt3 is involved with brain 
development, Pten is a negative regulator of Pi3k (dephosphorylates PIP3 to PIP2), 
nNos1 synthesizes nitric oxide, Jnk3 signals with beta-arrestin, and Abcc8, Abcc9, 
Kcnj8, Kcnj11v1, and Kcnj11 v2 are all KATP channel subunits, which is an octamer. 
While not all part of this pathway has been studied related to morphine tolerance, 
previous studies suggest there is no clear trend for all gene and expression can vary 
depending on the tissue (Cunha et al. 2010; Liu et al. 2006; Madishetti et al. 2014). 
We hypothesized that during morphine tolerance, there would be a decrease in gene 
expression in the PI3K/AKT intracellular signaling pathway, with potential increases 
in expression in Pten and Jnk3. There was a significant increase in gene expression in 
morphine mice compared to saline mice for Pik3cg v3 (1.64-fold increase; 
F3,16=111.1; p<0.0001), Pten (1.99-fold increase; F3,16=82.17; p<0.0001), Akt1 (1.67-
fold increase; F3,16=19.01; p<0.0001), Akt2 (1.81-fold increase; F3,16=65.78; 
p<0.0001), Akt3 (1.48-fold increase; F3,16=124; p<0.0001), and nNos1 (1.25-fold 
icrease; F3,16=89.13; p<0.0001) in the BS (Figure 8a-b, d). No significant differences 
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in gene expression were witnessed in the SC, DRGs, and SN (Figures 9, 10, & 11) 
(p>0.05). Tables 2-5 show the number of copies without normalization to Rn18s, with 
a summary of normalized and non-normalized gene expression levels in Tables 6 and 
7 respectively. Overall, there were significant increases in gene expression in 
morphine- vs saline-treated mice brainstem and varied expression in the spinal cord, 
dorsal root ganglia, and sciatic nerve. These findings did not support question 1 and 
the intial hypothesis as a decrease in gene expression during morphine tolerance was 
not whitnessed. 
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Figure 8. Significant increases in gene expression for MT vs saline mice were seen 
for Pik3cg v3, Pten, Akt1, Akt2, Akt3, and nNos1 in the brainstem. RT-qPCR analysis 
of genes of interest in morphine tolerant (15mg/kg, x2 day, 5 days) mice brainstems 
normalized with Rn18s. Data are expressed as concentration (morphine/saline) mean ± 
SEM. An ANOVA was performed with a Dunnett’s multiple comparisons test comparing 
mice subcutaneously injected with saline and morphine (n=5); *p<0.05; **p<0.01; 
***p<0.001; ****p<0.0001. 
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Gene 
Saline Mice 
 Mean Gene 
Expression 
(# of Copies) 
Saline 
Mice 
± SEM 
MT Mice 
Mean Gene 
Expression 
(# of Copies) 
MT 
Mice 
± SEM 
Rn18s 1.08E+07 1.41E+06 1.01E+07 2.08E+06 
Pik3cg v1 7.95E+02 7.56E+01 7.60E+02 6.29E+01 
Pik3cg v2 2.65E+04 5.07E+03 2.18E+04 8.14E+03 
Pik3cg v3 2.74E+03 5.02E+02 3.98E+03 6.97E+02 
Pten 8.98E+04 1.87E+04 1.61E+05 3.90E+04 
Akt1 2.23E+04 4.60E+03 3.64E+04 7.42E+03 
Akt2 5.78E+03 8.46E+02 1.02E+04 2.46E+03 
Akt3 3.74E+04 5.54E+03 4.85E+04 6.44E+03 
Abcc8 1.10E+03 1.69E+02 5.65E+02 6.70E+01 
Abcc9 4.46E+02 4.84E+01 5.45E+02 3.90E+01 
Kcnj8 3.96E+03 5.58E+02 2.53E+03 3.59E+02 
Kcnj11v1 8.45E+03 1.04E+03 5.39E+03 8.93E+02 
Kcnj11 v2 3.19E+03 3.79E+02 2.05E+03 2.75E+02 
Jnk3 9.13E+04 9.88E+03 5.90E+04 7.74E+03 
Oprm1 6.71E+02 9.21E+01 4.91E+02 8.73E+01 
nNOS1 2.83E+04 3.78E+03 3.49E+04 9.89E+03 
Table 2. Mean gene expression and SEM values from qPCR for the brainstem of 
saline and MT mice. Mean gene expression data (# of copies) and SEM from qPCR for 
the brainstem of saline and MT mice 
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Figure 9. No significant gene expression increases or decreases for MT vs saline 
mice were seen in the spinal cord. RT-qPCR analysis of genes of interest in morphine 
tolerant (15mg/kg, x2 day, 5 days) mice spinal cord normalized with Rn18s. Data are 
expressed as concentration (morphine/saline) mean ± SEM. An ANOVA was performed 
with a Dunnett’s multiple comparisons test comparing mice subcutaneously injected with 
saline and morphine (n=5);  
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Gene 
Saline Mice 
Mean Gene 
Expression (# of 
Copies) 
Saline 
Mice 
± SEM 
MT Mice 
Mean Gene 
Expression (# of 
Copies) 
MT 
Mice 
± SEM 
Rn18s 1.13E+07 1.67E+06 1.36E+07 3.00E+06 
Pik3cg v1 7.55E+02 2.96E+01 8.40E+02 6.08E+01 
Pik3cg v2 2.85E+04 3.74E+03 3.44E+04 7.76E+03 
Pik3cg v3 3.52E+03 2.27E+02 4.03E+03 1.11E+03 
Pten 1.07E+05 1.09E+04 1.71E+05 3.85E+04 
Akt1 2.88E+04 3.13E+03 1.86E+04 6.42E+03 
Akt2 4.39E+03 5.47E+02 5.90E+03 1.04E+03 
Akt3 3.89E+04 3.27E+03 4.25E+04 7.95E+03 
Abcc8 7.21E+02 2.33E+02 6.59E+02 4.65E+01 
Abcc9 8.08E+02 1.29E+02 3.99E+02 1.24E+02 
Kcnj8 2.70E+03 8.12E+02 3.08E+03 1.65E+02 
Kcnj11v1 5.08E+03 1.51E+03 7.02E+03 7.01E+02 
Kcnj11 v2 2.09E+03 4.31E+02 2.22E+03 2.00E+02 
Jnk3 4.37E+04 1.16E+04 6.35E+04 7.73E+03 
Oprm1 3.85E+02 1.14E+02 6.96E+02 9.28E+01 
nNOS1 2.15E+04 2.23E+03 2.42E+04 3.90E+03 
Table 3. Mean gene expression and SEM values from qPCR for the spinal cord of 
saline and MT mice. Mean gene expression data (# of copies) and SEM from qPCR for 
the spinal cord of saline and MT mice. 
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Figure 10. No significant gene expression increases or decreases for MT vs saline 
mice were seen in the dorsal root ganglia. RT-qPCR analysis of genes of interest in 
morphine tolerant (15mg/kg, x2 day, 5 days) mice dorsal root ganglia normalized with 
Rn18s. Data are expressed as concentration (morphine/saline) mean ± SEM. An ANOVA 
was performed with a Dunnett’s multiple comparisons test comparing mice 
subcutaneously injected with saline and morphine (n=5). 
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Gene 
Saline Mice 
Mean Gene 
Expression (# of 
Copies) 
Saline Mice 
± SEM 
MT Mice 
Mean 
Gene 
Expression 
(# of 
Copies) 
MT 
Mice 
± SEM 
Rn18s 6.63E+06 6.76E+05 7.58E+06 3.62E+05 
Pik3cg v1 3.60E+01 1.33E+01 7.63E+01 3.30E+01 
Pik3cg v2 2.80E+04 3.68E+03 3.40E+04 7.67E+03 
Pik3cg v3 6.06E+03 8.39E+02 9.24E+03 2.77E+02 
Pten 1.10E+05 1.56E+04 1.12E+05 9.80E+03 
Akt1 2.23E+04 5.58E+03 1.83E+04 2.85E+03 
Akt2 1.11E+04 1.64E+03 9.30E+03 1.55E+03 
Akt3 1.32E+05 2.38E+04 1.68E+05 1.53E+04 
Abcc8 4.60E+01 1.85E+01 9.96E+01 2.00E+01 
Abcc9 3.04E+02 7.68E+01 2.68E+02 3.32E+01 
Kcnj8 4.99E+02 8.05E+01 4.11E+02 3.24E+01 
Kcnj11v1 6.60E+02 1.26E+02 7.77E+02 1.31E+02 
Kcnj11 v2 1.83E+02 5.37E+01 3.00E+02 4.40E+01 
Jnk3 2.01E+05 1.35E+04 1.92E+05 2.02E+04 
Oprm1 2.43E+03 2.27E+02 2.54E+03 1.47E+02 
nNOS1 2.42E+04 2.84E+03 2.02E+04 3.58E+03 
Table 4. Mean gene expression and SEM values from qPCR for the dorsal root 
ganglia of saline and MT mice. Gene expression data (# of copies) and SEM from 
qPCR for the dorsal root ganglia of saline and MT mice. 
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Figure 11. No significant gene expression increases or decreases for MT vs saline 
mice were seen in the sciatic nerve. RT-qPCR analysis of genes of interest in morphine 
tolerant (15mg/kg, x2 day, 5 days) mice sciatic nerve normalized with Rn18s. Data are 
expressed as concentration (morphine/saline) mean ± SEM. An ANOVA was performed 
with a Dunnett’s multiple comparisons test comparing mice subcutaneously injected with 
saline and morphine (n=5). 
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Gene 
Saline Mice 
Mean Gene 
Expression (# 
of Copies) 
Saline Mice 
± SEM 
MT Mice 
Mean Gene 
Expression (# 
of Copies) 
MT 
Mice 
± SEM 
Rn18s 3.70E+06 5.11E+05 4.12E+06 5.34E+05 
Pik3cg v1 3.84E+01 1.37E+01 1.91E+01 4.62E+00 
Pik3cg v2 2.61E+04 4.99E+03 2.52E+04 6.33E+03 
Pik3cg v3 5.58E+03 1.35E+03 2.90E+03 5.18E+02 
Pten 1.77E+04 4.69E+03 1.99E+04 2.11E+03 
Akt1 7.94E+02 2.14E+02 5.63E+02 1.50E+02 
Akt2 3.06E+03 7.20E+02 8.26E+03 3.84E+03 
Akt3 3.25E+04 6.71E+03 3.17E+04 8.85E+03 
Abcc8 5.40E+00 1.16E+00 8.01E+00 2.91E+00 
Abcc9 1.56E+02 2.56E+01 2.92E+02 9.45E+01 
Kcnj8 3.53E+02 3.18E+01 4.35E+02 9.50E+01 
Kcnj11v1 2.50E+02 8.74E+01 8.54E+02 5.42E+02 
Kcnj11 v2 9.42E+01 1.62E+01 2.50E+02 1.26E+02 
Jnk3 3.12E+04 1.60E+03 2.79E+04 3.72E+03 
Oprm1 1.14E+03 5.62E+01 1.32E+03 2.79E+02 
nNOS1 6.90E+03 1.33E+03 8.64E+03 2.01E+03 
Table 5. Mean gene expression and SEM values from qPCR for the sciatic nerve of 
saline and MT mice. Gene expression data (# of copies) and SEM from qPCR for the 
sciatic nerve of saline and MT mice. 
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Gene Brainstem Spinal Cord Dorsal Root Ganglia Sciatic Nerve
Pik3cg v1 ↑ ↓
Pik3cg v2
Pik3cg v3 ↑**** ↑ ↓
Pten ↑**** ↑
Akt1 ↑* ↓ ↓ ↓
Akt2 ↑*** ↓ ↑
Akt3 ↑***
Abcc8 ↓ ↑ ↑
Abcc9 ↑ ↓ ↓ ↑
Kcnj8 ↓
Kcnj11v1 ↓ ↑ ↑
Kcnj11 v2 ↓ ↑ ↑
Jnk3 ↓ ↑
Oprm1 ↑
nNOS1 ↑* ↓
 
Table 6. Overview of normalized gene expression changes in MT mice for all tissues. 
Data are aggregated from Figures 8-11. Gene expression changes with normalizing to 
Rn18s. The arrows indicate whether there was an increase (up) or a decrease (down) in 
gene expression. Diagonal line shaded cells indicate at least a two-fold decrease and 
small circle shaded cells indicate at least a two-fold increase in gene expression. Blank 
boxes indicate a gene expression change less than 25%. *p<0.05; **p<0.01; ***p<0.001; 
****p<0.0001. 
 
48 
 
 
 
Table 7. Overview of non-normalized gene expression changes in MT mice for all 
tissues. Gene expression changes without normalizing to Rn18s. The arrows indicate 
whether there was an increase (up) or a decrease (down) in gene expression. Diagonal 
line shaded cells indicate at least a two-fold decrease and small circle shaded cells 
indicate at least a two-fold increase in gene expression. Blank boxes indicate a gene 
expression change less than 25%. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
 
Gene Brainstem Spinal Cord Dorsal Root Ganglia Sciatic Nerve
Pik3cg v1 ↑ ↓
Pik3cg v2
Pik3cg v3 ↑ ↑*** ↓*
Pten ↑
Akt1 ↑ ↓ ↓
Akt2 ↑ ↑ ↑
Akt3 ↑ ↑
Abcc8 ↓ ↑ ↑
Abcc9 ↓* ↑
Kcnj8 ↓
Kcnj11v1 ↓ ↑ ↑
Kcnj11 v2 ↓ ↓ ↑ ↑
Jnk3 ↓ ↑ ↓
Oprm1 ↓ ↑*
nNOS1 ↑
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cGMP Nucleotide Levels 
Since gene expression changes do not always correlate to changes in proteins and 
nucleotides, it was thought worthwhile to analyze cGMP nucleotide levels in saline- and 
morphine-treated mice. cGMP was chosen for analysis as it is responsible for activating 
protein kinase G (PKG), which phosphorylates and activates KATP channels either 
directly or through the ROS/calmodulin/CaMKII signaling cascade. cGMP nucleotide 
levels in saline and MT mice were analyzed in brainstems, spinal cords, dorsal root 
ganglia, trigeminal ganglia, and sciatic nerves using ELISA and compared back to saline 
mice (F4,70=64.56; p<0.0001) (Figure 12). Trigeminal ganglia were added to the analysis 
for cGMP nucleotide levels because of their proximity to the brainstem and the 
significant increases in gene expression that were seen in the brainstem of MT mice. 
While not all tissues have been studied prior, cGMP has been recorded to increase in the 
spinal cord after chronic morphine exposure (Liang and Clark 2004). We hypothesized 
cGMP nucleotide levels would decrease in MT mice as a decrease in cGMP would lower 
PKG activation, subsequently lowering KATP channel phosphorylation. There was a 
significant decrease in cGMP nucleotide levels in the sciatic nerve of MT mice compared 
to saline mice. There was no significant increase or decrease in cGMP protein levels for 
the brainstem, spinal cord, dorsal root ganglia, and trigeminal ganglia (p>0.05). 
Therefore, our results were consistent with our hypothesis for the sciatic nerve of MT 
mice, but not the brainstem, spinal cord, and dorsal root ganglia of MT mice. 
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Figure 12. Significant decrease in cGMP nucleotide levels was seen for MT vs saline 
mice sciatic nerve. ELISA analysis of cGMP levels in morphine tolerant (15mg/kg, x2 
day, 5 day) and saline (100 µL saline, x2 day, 5 days) brainstem (BS), trigeminal ganglia 
(TG), spinal cord (SC), dorsal root ganglia (DRG), and sciatic nerve (SN) tissues. Data 
are expressed as concentration (morphine/saline) mean ± SEM. An ANOVA with a 
Dunnett’s multiple comparisons test was used to compare mice subcutaneously injected 
with saline to MT mice (n=5). *p<0.05 
 
Tissue 
Saline Mice 
cGMP 
Concentration 
(pmol/µL) 
Saline Mice 
cGMP 
Concentration 
± SEM 
Morphine Mice 
cGMP 
Concentration 
(pmol/µL) 
Morphine Mice 
cGMP 
Concentration 
± SEM 
BS 1.96E+00 2.27E-01 2.26E+00 6.89E-01 
TG 3.42E-01 9.00E-02 4.87E-01 5.97E-02 
SC 5.40E-01 7.33E-02 8.22E-01 1.26E-01 
DRG 1.77E-01 4.70E-02 2.36E-01 4.48E-02 
SN 7.89E-01 7.26E-02 5.57E-01 6.28E-02 
Table 8. cGMP nucleotide levels and SEM values from ELISA analysis for the 
brainstem (BS), trigeminal ganglia (TG), spinal cord (SC), dorsal root ganglia 
(DRG), and sciatic nerve (SN) of saline and MT mice. 
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Summary of Morphine Tolerance (Question #1) 
Overall, the goal of the first question was to determine whether gene expression of 
the PI3K/AKT pathway decreased in MT mice compared to saline mice. TPWL was 
utilized to ensure the tissues that were harvested and used for gene expression analysis 
were tolerant to morphine, which developed by day 3. There were significant increases in 
gene expression for Pik3cg v3, Pten, Akt1, Akt2, Akt3, and nNos1 in MT mice brainstem 
compared to saline mice, with no significant changes in the spinal cord, dorsal root 
ganglia, and sciatic nerve. Additionally, cGMP nucleotide activity analysis indicated a 
significant decrease only in the sciatic nerve of MT mice. Therefore, our hypothesis for 
question 1 was not supported as gene expression either significantly increased in the 
brainstem or had varied expression in the other nervous system tissues. 
 
2. Morphine Tolerance + Spinal Nerve Ligation (Question #2) 
Thermal Paw Latency in Morphine Tolerant Mice with Spinal Nerve Ligation 
Spinal nerve ligated mice with the addition of morphine tolerance were used as an 
opioid induced tolerance neuropathic pain model. The purpose of the behavior testing 
was to ensure the MT+SNL mice developed morphine tolerance. The Injured (i.e. 
Ipsilateral, “Ipsi”) and uninjured (i.e. contralateral, “Contra”) sides of the MT+SNL mice 
were compared to each other during behavioral testing to analyze the effects of the spinal 
nerve ligation. Past research has suggested the ipsi side of the mouse will have lower 
TPWL than the contra side of MT+SNL mice (Kitagawa et al. 2005). Behavior testing for 
the ipsi and contra sides of the MT+SNL mice on days 0, 1, 3, and 5 were not 
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significantly different from each other 30 minutes post injections (F1,76=0.8935; 
p=0.3475) (Figure 13). Additionally, when comparing the pretest data to that of days 1, 3, 
and 5, morphine tolerance developed by day 3, which was consistent with the non-SNL 
MT mice. Thus, the development of opioid induced tolerance in the spinal nerve ligated 
mice insured the mice were morphine tolerant before being harvested for gene expression 
analysis to analyze question 2. 
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Figure 13. No significant differences were seen in TPWL reaction times for ipsi and 
contra sides of MT+SNL mice. TPWL threshold data (seconds) for morphine tolerant 
SNL mice (15mg/kg, x2 day, 5 days) 30 minutes post-injection. Data are expressed as 
mean ± SEM. An ANOVA with a Dunnett’s multiple comparisons test was used to 
compare injured (i.e. ipsilateral, “ipsi”; circles) and uninjured (i.e. contralateral, “contra”; 
squares) sides for days 1 (including pretest), 3, and 5 of MT+SNL mice (F1,76=0.8935; 
p=0.3475) (n=6). 
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Gene Expression 
Gene expression for the MT+SNL was assessed for the same 15 genes and tissues 
in the same tissues as the MT and saline mice using RT-qPCR (Figures 14-17, Tables 9-
12). The purpose of analyzing gene expression of the MT+SNL mice was to analyze how 
the addition of the spinal nerve ligation alters gene expression in mice with opioid 
induced tolerance and whether the side in which the ligation occurred alters gene 
expression. The MT+SNL mice (ipsi and contra) gene expression were compared back to 
saline treated mice as acute morphine SNL mice would not show gene expression 
changes as tolerance develops by day three. While no significant differences were 
witnessed for the ipsi and contra sides in the TPWL tests, both were still used for RT-
qPCR as previous have found differences between ipsi and contra chronic pain KATP 
channels (Luu et al. 2019). Thus, our results assume that the effects witnessed within are 
caused by the addition of the morphine tolerance to the SNL and not just the SNL alone. 
We hypothesize there would be an overall decrease in gene expression (except for Pten 
and Jnk3) for the MT+SNL mice compared to the saline treated mice. There was a 
significant decrease in gene expression in MT+SNL mice (ipsi and contra) compared to 
saline-treated non-SNL mice for Pik3cg v1 (200-fold decrease ipsi, 200-fold decrease 
contra; F3,16=17.87; p<0.0001), Pik3cg v2 (167-fold decrease ipsi, 125-fold decrease 
contra; F3,16=5.532; p=0.0084), Akt2 (500-fold decrease ipsi, 1,000-fold decrease contra; 
F3,16=58.75; p<0.0001), and Akt3 (100-fold decrease ipsi, 143-fold decrease contra; 
F3,16=36.18; p<0.0001) in the BS (Figure 14). There were also significant increases in 
expression in ipsi MT+SNL mice and contra MT+SNL mice compared to saline-treated 
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mice for Akt1 (40-fold decrease ipsi, 5-fold decrease contra; F3,16=45.06; p<0.0001), 
Abcc8 (1.06-fold increase ipsi, 1.28-fold decrease contra; F3,16=35.38; p<0.0001), Abcc9 
(3.44-fold decrease ipsi, 4.76-fold decrease contra; F3,16=14.99; p<0.0001), Kcnj11 v1 
(8.33-fold decrease ipsi, 11.49-fold decrease contra; F3,16=50.87; p<0.0001), Kcnj11 v2 
(5.20-fold decrease ipsi, 6.45-fold decrease contra; F3,16=59.23; p<0.0001), Jnk3 (14.08-
fold decrease ipsi, 16.67-fold decrease contra; F3,16=11.73; p=0.0003), Oprm1 (2.08-fold 
decrease ipsi, 2.12-fold decrease contra; F3,16=14.57; p<0.0001), and ipsi nNos1 (26.32-
fold decrease ipsi; F3,16=2.804; p=0.0733) and Kcnj8 (24.39-fold decrease ipsi; 
F3,16=8.250; p=0.0015) in the BS (Figure 14). In the SC of MT+SNL mice, there was a 
decrease in gene expression in the SC for Pik3cg v1 (13.89-fold decrease ipsi, 9.09-fold 
decrease contra; F3,16=19.74; p<0.0001), Pik3cg v2 (111.11-fold decrease ipsi, 333.33-
fold decrease contra; F3,16=17.82; p<0.0001), Pik3cg v3 (25-fold decrease ipsi, 50-fold 
decrease contra; F3,16=19.44; p<0.0001), Akt1 (20-fold decrease ipsi, 12.5-fold decrease 
contra; F3,16=9.788; p=0.0007), Akt2 (26.32-fold decrease ipsi, 26.32-fold decrease 
contra; F3,16=19.65; p<0.0001), Akt3 (58.82-fold decrease ipsi, 52,63-fold decrease 
contra; F3,16=42.65; p<0.0001), Abcc9 (10.52-fold decrease ipsi, 8.33-fold decrease 
contra; F3,16=6.081; p=0.0058), Kcnj11 v2 (47.62-fold increase ipsi, 31.25-fold decrease 
contra; F3,16=7.505; p=0.0024), Jnk3 (50-fold decrease ipsi, 43.47-fold decrease contra; 
F3,16=7.316; p=0.0026), nNos1 (41.67-fold decrease ipsi, 27.78-fold decrease contra; 
F3,16=44.82; p<0.0001), and ipsi Kcnj11 v1 (21.74-fold decrease ipsi; F3,16=6.295; 
p=0.0050) (Figure 15a-d). In the DRG of MT+SNL mice, there was a significant increase 
in expression when compared to saline mice for ipsi and contra Abcc8 (135.0-fold 
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increase ipsi, 155.1-fold increase contra; F3,16=11.18; p=0.0003), with an increase in the 
contra side for Pik3cg v2 (7.81-fold increase contra; F3,16=3.646; p=0.0354) and Kcnj8 
(20.56-fold increase contra; F3,16=6.618; p=0.0041), an increase in the ipsi side for 
Kcnj11 v2 (25.50-fold increase ipsi; F3,16=3.780; p=0.0318), and a decrease in the contra 
side of Akt2 (1.89-fold decrease contra; F3,16=4.363; p=0.0200) (Figure 16a-c). No 
significant differences in gene expression were witnessed in the SN (p>0.05) (Figure 17). 
Tables 8-11 show the number of copies without normalization, with a summary of 
normalized and non-normalized gene expression levels in Table 13 and 14 respectively. 
Overall, there were significant decreases in gene expression in the spinal cord, increased 
expression in the sciatic nerve, and varied expression in the brainstem and dorsal root 
ganglia. Therefore, our results do not support question 2 for every tissue as only spinal 
cord saw a decrease in the PI3K/AKT pathway.  
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Figure 14. Significant decreases in gene expression for ipsi and contra sides of 
MT+SNL-treated mice brainstems were seen for Pik3cg v1, Pik3cg v2, Akt2, and 
Akt3, with increases in Akt1, Abcc8, Abcc9, Kcnj11 v1, Kcnj11 v2, Jnk3, Oprm1, and 
increases on the ipsi side only for Kcnj8 and nNos1. RT-qPCR analysis of morphine 
tolerant (15mg/kg, x2 day, 5 days) mice with SNL brainstem normalized with Rn18s. 
Data are expressed as concentration (ipsi or contra/saline) mean ± SEM. An ANOVA 
was performed with a Dunnett’s multiple comparisons test comparing mice 
subcutaneously injected with saline to MT+SNL mice (ipsi and contra) (n=5); **p<0.01; 
***p<0.001; ****p<0.0001. 
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Gene 
Ipsi MT+SNL 
Mean gene 
expression (# of 
copies) 
Ipsi MT+SNL 
± SEM 
Contra 
MT+SNL 
Mean gene 
expression 
(# of copies) 
Contra 
MT+SNL 
± SEM 
Rn18s 7.52E+06 1.37E+06 7.38E+06 5.42E+05 
Pik3cg v1 1.56E+02 3.07E+01 1.55E+02 1.68E+01 
Pik3cg v2 5.67E+03 1.16E+03 8.72E+03 7.60E+02 
Pik3cg v3 1.26E+03 2.49E+02 1.67E+03 3.73E+02 
Pten 3.67E+04 7.93E+03 3.61E+04 1.02E+04 
Akt1 2.11E+05 4.34E+04 1.95E+05 3.06E+04 
Akt2 4.00E+02 6.77E+01 2.94E+02 4.36E+01 
Akt3 1.35E+04 3.51E+03 1.01E+04 1.63E+03 
Abcc8 4.05E+04 6.97E+03 3.44E+04 2.55E+03 
Abcc9 4.92E+03 1.46E+03 3.83E+03 5.32E+02 
Kcnj8 6.14E+03 1.59E+03 4.69E+03 7.04E+02 
Kcnj11v1 3.63E+04 6.27E+03 3.04E+04 2.86E+03 
Kcnj11 v2 2.23E+04 3.79E+03 2.03E+04 1.73E+03 
Jnk3 2.52E+05 7.31E+04 2.36E+05 4.94E+04 
Oprm1 1.28E+04 4.55E+03 1.30E+04 2.04E+03 
nNOS1 3.64E+04 7.21E+03 2.94E+04 4.63E+03 
Table 9. Mean gene expression and SEM values from qPCR for the brainstem of the 
ipsi and contra sides of MT+SNL mice. Gene expression data (# of copies) and SEM 
from qPCR for the brainstem of the ipsi and contra sides of MT+SNL mice. 
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Figure 15. Significant decreases in gene expression for ipsi and contra sides of 
MT+SNL treated mice spinal cord were seen for Pik3cg v1, Pik3cg v2, Pik3cg v3, 
Akt1, Akt2, Akt3, Abcc9, Kcnj11 v2, Jnk3, and nNos1, with a decrease of the ipsi side 
for Kcnj11 v1. RT-qPCR analysis of morphine tolerant (15mg/kg, x2 day, 5 days) mice 
with SNL spinal cord normalized with Rn18s. Data are expressed as concentration (ipsi 
or contra/saline) mean ± SEM. An ANOVA was performed with a Dunnett’s multiple 
comparisons test comparing mice subcutaneously injected with saline to MT+SNL mice 
(ipsi and contra). (n=5); *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
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Gene 
Ipsi MT+SNL 
Mean gene 
expression (# of 
copies) 
Ipsi MT+SNL 
± SEM 
Contra 
MT+SNL 
Mean gene 
expression 
(# of copies) 
Contra 
MT+SNL 
± SEM 
Rn18s 1.84E+07 7.16E+06 9.69E+06 3.78E+06 
Pik3cg v1 3.25E+01 4.22E+00 2.48E+01 3.99E+00 
Pik3cg v2 1.47E+02 2.26E+01 5.45E+01 2.15E+01 
Pik3cg v3 9.64E+01 1.95E+01 4.49E+01 1.20E+01 
Pten 8.26E+04 1.03E+04 5.54E+04 8.20E+03 
Akt1 2.04E+03 1.01E+03 1.64E+03 6.29E+02 
Akt2 8.49E+01 4.57E+00 6.24E+01 4.25E+00 
Akt3 5.23E+02 1.03E+02 3.51E+02 4.22E+01 
Abcc8 2.96E+02 1.87E+02 2.16E+02 1.04E+02 
Abcc9 5.91E+01 1.64E+01 4.97E+01 1.29E+01 
Kcnj8 2.09E+02 1.98E+01 2.11E+02 1.02E+01 
Kcnj11v1 3.24E+02 1.81E+02 3.50E+02 1.78E+02 
Kcnj11 v2 7.58E+01 4.99E+01 8.33E+01 4.82E+01 
Jnk3 1.46E+03 7.91E+02 8.83E+02 3.65E+02 
Oprm1 1.17E+02 4.66E+01 1.13E+02 3.67E+01 
nNOS1 4.36E+02 1.29E+02 4.23E+02 9.44E+01 
Table 10. Mean gene expression and SEM values from qPCR for the spinal cord of 
the ipsi and contra sides of MT+SNL mice. Gene expression data (# of copies) and 
SEM from qPCR for the spinal cord of the ipsi and contra sides of MT+SNL mice. 
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Figure 16. Gene expression increases for the dorsal root ganglia were seen for the 
contralateral sides of Pik3cg v2, Abcc8, Kcnj8, and the ipsilateral side of Abcc8 and 
Kcnj11 v2, with decreases in the contralateral side of Akt2 in MT+SNL mice. RT-
qPCR analysis of morphine tolerant (15mg/kg, x2 day, 5 days) mice with SNL dorsal root 
ganglia normalized with Rn18s. Data are expressed as concentration (ipsi or 
contra/saline) mean ± SEM. An ANOVA was performed with a Dunnett’s multiple 
comparisons test comparing mice subcutaneously injected with saline to MT+SNL mice 
(ipsi and contra). (n=5); *p<0.05; **p<0.01. 
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Gene 
Ipsi MT+SNL 
Mean gene 
expression (# of 
copies) 
Ipsi MT+SNL 
± SEM 
Contra 
MT+SNL 
Mean gene 
expression 
(# of copies) 
Contra 
MT+SNL 
± SEM 
Rn18s 1.41E+06 4.12E+05 4.91E+05 1.70E+05 
Rn18s* 1.89E+07 1.41E+07 1.77E+06 3.87E+05 
Rn18s** 1.41E+06 4.12E+05 4.81E+05 1.60E+05 
Pik3cg v1* 2.90E+02 1.50E+02 1.55E+02 6.64E+01 
Pik3cg v2 1.94E+04 3.39E+03 1.03E+04 1.54E+03 
Pik3cg v3 4.02E+02 3.28E+01 3.58E+02 4.46E+01 
Pten 8.26E+04 1.03E+04 5.54E+04 8.20E+03 
Akt1 5.86E+03 1.20E+03 3.04E+03 4.88E+02 
Akt2 3.91E+02 4.11E+01 2.63E+02 2.48E+01 
Akt3 1.84E+04 3.61E+03 5.57E+03 7.77E+02 
Abcc8** 9.73E+02 2.78E+02 4.94E+02 2.04E+02 
Abcc9* 6.39E+01 1.68E+01 5.43E+01 1.33E+01 
Kcnj8** 1.34E+03 3.99E+02 8.38E+02 2.91E+02 
Kcnj11v1** 6.91E+01 8.63E+00 2.21E+01 5.49E+00 
Kcnj11 v2** 6.08E+02 1.05E+02 2.08E+02 4.13E+01 
Jnk3* 6.32E+04 1.46E+04 3.45E+04 8.29E+03 
Oprm1** 5.42E+02 4.18E+01 5.27E+02 2.33E+01 
nNOS1 6.75E+03 1.77E+03 3.48E+03 1.16E+03 
Table 11. Mean gene expression and SEM values from qPCR for the dorsal root 
ganglia of the ipsi and contra sides of MT+SNL mice. Mean gene expression data (# of 
copies) and SEM from qPCR for the dorsal root ganglia of the ipsi and contra sides of 
MT+SNL mice. “* and **” denotes samples that were made from new cDNA and a new 
Rn18s. 
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Figure 17. No significant gene expression differences for the ipsi and contra sides of 
MT+SNL mice were seen in the sciatic nerve. RT-qPCR analysis of morphine tolerant 
(15mg/kg, x2 day, 5 days) mice with SNL sciatic nerve normalized with Rn18s. Data are 
expressed as concentration (ipsi or contra/saline) mean ± SEM. An ANOVA was 
performed with a Dunnett’s multiple comparisons test comparing mice subcutaneously 
injected with saline to MT+SNL mice (ipsi and contra). (n=5). 
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Gene 
Ipsi MT+SNL 
Mean gene 
expression (# of 
copies) 
Ipsi MT+SNL 
± SEM 
Contra 
MT+SNL 
Mean gene 
expression 
(# of copies) 
Contra 
MT+SNL 
± SEM 
Rn18s 6.43E+05 2.79E+05 1.77E+06 1.43E+06 
Rn18s* 1.25E+06 4.66E+05 7.85E+05 3.09E+05 
Rn18s** 6.39E+05 2.81E+05 1.77E+06 1.43E+06 
Pik3cg v1* 3.55E+02 1.24E+02 3.10E+02 2.41E+01 
Pik3cg v2 1.06E+04 3.65E+03 1.04E+04 1.57E+03 
Pik3cg v3 3.71E+02 6.74E+01 3.20E+02 3.33E+01 
Pten 3.67E+04 7.93E+03 3.61E+04 1.02E+04 
Akt1 3.19E+03 8.88E+02 2.46E+03 7.61E+02 
Akt2 9.91E+02 2.93E+02 2.53E+02 3.12E+01 
Akt3 1.18E+04 2.65E+03 5.19E+03 2.05E+03 
Abcc8** 3.34E+03 3.10E+03 1.64E+02 4.41E+01 
Abcc9* 4.72E+03 1.40E+03 3.69E+03 5.07E+02 
Kcnj8** 1.16E+02 1.46E+01 1.05E+02 1.30E+01 
Kcnj11v1** 5.37E+01 1.05E+01 6.23E+01 1.44E+01 
Kcnj11 v2** 2.30E+02 4.47E+01 1.48E+02 3.28E+01 
Jnk3* 2.52E+05 7.31E+04 2.36E+05 4.94E+04 
Oprm1** 4.98E+02 1.64E+01 2.92E+02 4.35E+01 
nNOS1 2.06E+03 9.06E+02 1.32E+03 4.76E+02 
Table 12. Mean gene expression and SEM values from qPCR for the sciatic nerve of 
the ipsi and contra sides of MT+SNL mice. Mean gene expression data (# of copies) 
and SEM from qPCR for the sciatic nerve of the ipsi and contra sides of MT+SNL mice. 
“* and **” denotes samples that were made from new cDNA and a new Rn18s. 
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Gene Ipsi Contra Ipsi Contra Ipsi Contra Ipsi Contra
Pik3cg v1 ↓*** ↓*** ↓*** ↓*** ↑ ↑ ↑ ↑
Pik3cg v2 ↓** ↓* ↓*** ↓*** ↑ ↑* ↑ ↑
Pik3cg v3 ↓ ↓*** ↓*** ↓ ↑ ↑
Pten ↓ ↓ ↑ ↑ ↑ ↑ ↑
Akt1 ↑**** ↑**** ↓** ↓** ↑ ↑ ↑ ↑
Akt2 ↓**** ↓**** ↓*** ↓*** ↓ ↓** ↑ ↑
Akt3 ↓**** ↓**** ↓**** ↓**** ↑ ↑
Abcc8 ↑**** ↑**** ↓ ↓ ↑** ↑** ↑ ↑
Abcc9 ↑*** ↑** ↓** ↓** ↓ ↓ ↑ ↑
Kcnj8 ↑** ↑ ↓ ↓ ↑ ↑** ↑ ↑
Kcnj11v1 ↑**** ↑**** ↓* ↓ ↓ ↓ ↑ ↑
Kcnj11 v2 ↑**** ↑**** ↓** ↓* ↑* ↑ ↑ ↑
Jnk3 ↑** ↑** ↓* ↓* ↓ ↓ ↑ ↑
Oprm1 ↑** ↑*** ↓ ↓ ↑ ↑ ↑ ↑
nNOS1 ↑* ↑ ↓**** ↓**** ↑ ↑ ↑ ↑
Brainstem Spinal Cord Dorsal Root Ganglia Sciatic Nerve
 
Table 13. Overview of normalized gene expression changes in MT+SNL mice for all 
tissues. Aggregation of data from Figures 14-17. Gene expression changes normalized 
with Rn18s. The arrows indicate whether there was an increase (up) in gene expression or 
a decrease (down) compared to saline mice tissues. Diagonal lines indicate at least a two-
fold decrease and small circles indicate at least a two-fold increase in gene expression 
compared to saline mice tissues. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 
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Gene Ipsi Contra Ipsi Contra Ipsi Contra Ipsi Contra
Pik3cg v1 ↓****↓****↓****↓****↑ ↑ ↑ ↑
Pik3cg v2 ↓* ↓ ↓*** ↓*** ↓ ↓* ↓ ↓
Pik3cg v3 ↓ ↓** ↓** ↓****↓****↓*** ↓***
Pten ↓ ↓ ↓ ↓** ↑ ↑
Akt1 ↑*** ↑*** ↓*** ↓*** ↓** ↓** ↑ ↑*
Akt2 ↓* ↓* ↓*** ↓*** ↓****↓****↓ ↓
Akt3 ↓** ↓** ↓****↓****↓*** ↓****↓ ↓*
Abcc8 ↑****↑****↓ ↓ ↑** ↑ ↑ ↑
Abcc9 ↑** ↑* ↓****↓****↓** ↓** ↑** ↑*
Kcnj8 ↓** ↓** ↑ ↑ ↓* ↓**
Kcnj11v1 ↑*** ↑** ↓** ↓** ↓*** ↓*** ↓ ↓
Kcnj11 v2 ↑****↑****↓****↓****↑*** ↑ ↑
Jnk3 ↑ ↑ ↓** ↓** ↓****↓****↓****↓****
Oprm1 ↑** ↑** ↓ ↓ ↓****↓****↓* ↓**
nNOS1 ↓****↓****↓*** ↓****↓* ↓*
Brainstem Spinal Cord Dorsal Root Ganglia Sciatic Nerve
 
Table 14. Overview of non-normalized gene expression changes in MT+SNL mice 
for all tissues. Gene expression changes not normalized with Rn18s. The arrows indicate 
whether there was an increase (up) in gene expression or a decrease (down) compared to 
saline mice tissues. Diagonal lines indicate at least a two-fold decrease and small circles 
indicate at least a two-fold increase in gene expression compared to saline mice tissues. 
*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 
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cGMP Nucleotide Levels 
Since gene expression changes do not always correlate to changes in proteins and 
second messengers, it was thought worthwhile to analyze cGMP nucleotide levels in ipsi 
and contra side in MT+SNL and compare them back to non-SNL saline treated mice. As 
with the cGMP analysis for question 1, cGMP was chosen for analysis as it is responsible 
for activating protein kinase G (PKG), which phosphorylates and activates KATP channels 
either directly or through the ROS/calmodulin/CaMKII signaling cascade. While there is 
not any previous reports of cGMP levels in MT+SNL mice, there is a previous study that 
found spinal cGMP increases in SNL mice (Siegan, Hama, and Sagen 1996). cGMP 
levels for the ispi and contra sides of MT + SNL mice were analyzed for brainstem (BS), 
trigeminal ganglia (TG), spinal cord (SC), dorsal root ganglia (DRG), and sciatic nerve 
(SN) using ELISA and compared back to saline mice (F4,70=64.56; p<0.0001) (Figure 18, 
Table 15). We hypothesized cGMP nucleotide levels would decrease in the ipsi and 
contra side of MT+SNL mice when compared back to saline treated non-SNL mice as a 
decrease in cGMP could lead to less phosphorylated KATP channels. The ipsi and contra 
spinal cord of MT + SNL mice had significant increases in cGMP when compared to 
saline mice spinal cords. Additionally, the ipsi and contra sciatic nerve of MT + SNL 
mice had significant decreases in cGMP when compared to saline mice sciatic nerves. 
There was no significant difference for the brainstem, dorsal root ganglia, and trigeminal 
ganglia (p>0.05). Overall, our results did not support question 2 for all tissues as there 
was an increase in cGMP nucleotide levels in the spinal cord and a decrease in the sciatic 
nerve of MT+SNL mice. 
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Figure 18. Significant increases in cGMP levels were seen in the spinal cord and 
significant decreases in cGMP levels were seen in the sciatic nerve of ipsi and contra 
MT+SNL vs saline mice. ELISA analysis of cGMP levels in MT + SNL (15mg/kg, x2 
day, 5 day) brainstem (BS), trigeminal ganglia (TG), spinal cord (SC), dorsal root ganglia 
(DRG), and sciatic nerve (SN) tissues. Data are expressed as concentration (contra or 
ipsi/saline) mean ± SEM. An ANOVA with a Dunnett’s multiple comparisons test was 
used to compare mice subcutaneously injected with saline to MT+SNL (ipsi and contra) 
mice (n=5); ****p<0.0001. 
 
 
Tissue 
Ipsi MT+SNL 
cGMP 
Concentration 
(pmol/µL) 
Ipsi MT+SNL 
cGMP 
Concentration 
± SEM 
Contra MT+SNL 
cGMP 
Concentration 
(pmol/µL) 
Contra 
MT+SNL 
cGMP 
Concentration 
± SEM 
BS 1.55E+00 1.53E-01 1.57E+00 1.98E-01 
TG 2.71E-01 1.21E-02 2.64E-01 3.68E-02 
SC 3.92E+00 9.71E-01 5.03E+00 5.99E-01 
DRG 1.61E-01 2.18E-02 2.00E-01 2.72E-02 
SN 1.95E-01 3.81E-02 2.23E-01 4.61E-02 
Table 15. Mean concentration and SEM values from ELISA analysis for the 
brainstem (BS), trigeminal ganglia (TG), spinal cord (SC), dorsal root ganglia 
(DRG), and sciatic nerve (SN) of the ipsi and contra sides of MT+SNL mice. 
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Morphine Tolerance with Spinal Nerve Ligation Summary  
Overall, the goal of the second question was to determine whether gene expression of 
the PI3K/AKT pathway decreased in MT+SNL mice compared to non-SNL saline mice. 
TPWL was utilized to ensure the tissues that were harvested and used for gene expression 
analysis were tolerant to morphine, which developed by day 3. There were significant 
decreases in gene expression for Pik3cg v1, Pik3cg v2, Akt1, and Akt2 in MT+SNL mice 
brainstem compared to saline mice, decreases in gene expression in all genes except Pten 
in the spinal cord, varied gene expression dorsal root ganglia, and increases in gene 
expression in the sciatic nerve. Additionally, cGMP nucleotide activity analysis indicated 
a significant increase in the spinal cord and a decrease in the sciatic nerve of MT+SNL 
mice compared to saline-treated mice. Therefore, our hypothesis for question 2 was 
partially supported as gene expression decreased in the spinal cord of MT+SNL mice and 
cGMP nucleotide levels in the sciatic nerve of MT+SNL mice decreased. 
 
3. PI3K Pathway Inhibitors 
Behavior Testing 
To analyze question 3, spinal nerve ligated mice were utilized as the most 
significant gene expression changes from the RT-qPCR results were seen in the 
MT+SNL mice. The purpose of this experiment was to determine whether the inhibition 
of parts of the PI3K/AKT pathway during morphine administration would alter the 
development of opioid induced tolerance. Previous studies have found that thalidomide, 
SP600125, and quercetin attenuate morphine tolerance in 100 mg/kg, 10 mg/kg, and 60 
mg/kg respectively twice daily (Hassanzadeh et al. 2016; Hervera, Leánez, and Pol 2012; 
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Naidu et al. 2003). Thus, the injured (ipsi) (F3,24=34.15; p<0.0001) and uninjured (contra) 
(F3,24=16.61; p<0.0001) sides of the MT+SNL mice were compared for thalidomide, 
quercetin, SP600125, and the vehicle. We hypothesized inhibiting the PI3K/AKT 
pathway would increase or maintain opioid induced tolerance for thalidomide or 
quercetin as they would decrease PI3K/AKT pathway activity and potentially lower the 
amount of phosphorylated KATP channels. Additionally, we hypothesized SP600125 
would attenuate morphine tolerance as the inhibition of the phosphorylation of JNK could 
potentially drive phosphorylation towards the KATP channels. The ipsi and contra sides 
had the same TPWL prior to any drug injections (pre-test; p>0.05) (Figure 19a-b). For the 
ipsi side on day one, only thalidomide had a significant increase on the TPWL when 
compared back to the vehicle (p<0.05). On day three for the ipsi side, both quercetin and 
SP600125 significantly increased TPWL time (p<0.001 and p<0.05 respectively). On day 
five for the ipsi side, thalidomide, quercetin, and SP600125 significantly increased 
TPWL time (p<0.001). For the contra side, days one and three saw no significant 
difference when compared back to the vehicle (p>0.05), while on day 5, thalidomide, 
quercetin, and SP600125 had significantly increased TPWL (p<0.001). Overall, our 
results support question 3 for SP600125, but not thalidomide and quercetin as all drugs 
attenuated the development of morphine tolerance by day 5 in the ipsi and contra sides of 
SNL mice given chronic morphine.  
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Figure 19. PI3K/AKT pathway inhibitors attenuated the development of morphine 
tolerance by day 5 in MT+SNL mice. PI3K/AKT pathway inhibitor TPWL threshold 
data for injured (i.e. ipsilateral, “ipsi”) (a) and uninjured (i.e. contralateral, “contra”) (b) 
sides of MT+SNL mice (15mg/kg, x2 day, 5 day) given the vehicle (circle; 20% DMSO, 
5% Tween 20, 75% saline; 30 mins prior to morphine inj.), or one of the PI3K/AKT 
pathway inhibitors: quercetin (upward triangle; PI3Kcg inhibitor; 60mg/kg; 100% saline; 
30 mins prior to morphine inj.), thalidomide (square; PI3K/AKT/nNOS inhibitor; 
100mg/kg; 10% DMSO, 90% saline; 15 mins prior to morphine inj.), or SP600125 
(downward triangle; JNK inhibitor; 10mg/kg; 20% DMSO, 5% Tween 20, 75% saline; 30 
mins prior to morphine inj.). Data are expressed as mean ± SEM. Repeated measures 
ANOVA for both ipsi and contra using a Dunnett post-hoc test to compare back to the 
vehicle (n=5). *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
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Discussion 
The management of chronic pain with opioids can cause opioid-induced analgesic 
tolerance and hyperalgesia, which complicates clinical pain-management treatments. 
Although G-protein coupled receptors, and specifically mu opioid receptors (MOPs), 
have been studied for decades, the intracellular signaling pathways triggered by the 
activation of MOPs, as well as downstream targets, still need more clarification. 
Recently, our lab has shown that a suggested downstream target of MOP signaling, KATP 
channels with the SUR1(Abcc8) subunit, reduce opioid induced tolerance when KATP 
channel activity is increased by a SUR1 agonist (Fisher et al. 2019). Additionally, recent 
studies have found that the PI3K/AKT intracellular signaling pathway is involved with 
KATP channel activity and may be linked to the pain relief effects of opioids in neuronal 
cells, specifically pain related to inflammation (Cunha et al. 2010). Therefore, we sought 
to determine whether opioid induced tolerance is linked to a decreased activity in the 
PI3K/AKT intracellular signaling pathway in MT and MT+SNL mice (Figure 1). This 
section will discuss our results in the context of opioid induced tolerance at behavioral 
and molecular levels. The discussion is divided into MT vs saline-treated mice to address 
whether gene expression/cGMP nucleotide levels within the PI3K/AKT intracellular 
signaling pathway decrease during morphine tolerance (question 1), MT+SNL vs saline-
treated mice to analyze whether neuropathic chronic pain in addition to morphine 
tolerance (MT+SNL) cause a decrease gene expression/cGMP nucleotide levels (question 
2), and  PI3K/AKT pathway inhibitors vs vehicle-treated mice to determine if inhibiting 
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proteins or enzymes within the PI3K/AKT intracellular signaling pathway exacerbates 
the development of morphine tolerance (question 3). 
Morphine Tolerant (MT) Mice vs Saline-treated mice (Question 1) 
1. MT Gene Expression Varies Across Tissues 
 Our data for RT-qPCR was normalized to Rn18s to account for variability in 
RNA quality or RT efficiency, and because it has less variance in expression compared to 
other housekeeping genes such as GAPDH and β-actin. Comparing relative abundances 
values of the normalized data to the non-normalized for all experiments (saline, MT, 
MT+SNLipsi, and MT+SNLcontra mice), there were some discrepancies and changes in the 
gene expression values (Tables 6-7, 13-14). These changes can be attributed to the 
different Rn18s values seen when comparing saline to MT and MT+SNL (ipsi and 
contra) mice. However, an ANOVA with a Dunnett’s multiple comparisons test was used 
to compare Rn18s data for mice subcutaneously injected with saline to MT and MT+SNL 
(ipsi and contra) mice and found no significant differences between treatments 
(F3,64=2.187; p=0.0981). Therefore, the normalized data was used as the basis for the 
gene expression discussion. 
Gene expression levels in the BS, SC, DRG, and SN of saline mice vs MT mice 
were analyzed. This discussion section related to gene expression fold changes is 
separated out by gene. Our lab found a significant increase in gene expression in the BS, 
with no significant differences in gene expression found in the SC, DRG, and SN when 
compared back to saline mice (Figures 8-11; Table 6). The lack of changes in gene 
expression in the SC, DRG, and SN, and the presence of changes in the BS suggests the 
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BS may be more involved with the PI3K/AKT pathway than the peripheral nervous 
system (PNS) during morphine tolerance. However, the fold changes in gene expression 
within the MT mice vs saline mice were modest, with all fold changes being less than 3. 
Therefore, while there were significant increases in gene expression in the BS of MT 
mice, the modest levels of fold changes within these tissues may not actually correlate to 
important changes.  
 The discovery of Pik3cg v3 being significantly upregulated in the BS of MT mice 
compared to the other Pik3cg variants was an unexpected discovery (Figure 8a; Table 6). 
In general, Pik3cg has been previously studied for its role in MT, with findings 
suggesting that Pik3cg activity increases in the DRGs of MT mice (Cunha et al. 2010; 
König et al. 2010; Madishetti et al. 2014). Additionally, the less than 2 fold increases in 
DRG for Pik3cg v1 and v3 are consistent with past research that found general Pik3cg 
activity increases during MT in DRG (König et al. 2010). Compared to the other variants, 
Pik3cg v2 had no change among all the tissues analyzed (Table 6). Additionally, Pik3cg 
v1 and Pik3cg v3 had no clear trend for the CNS and PNS. When comparing these 
findings back to our hypothesis for question one, we did not see a decrease in gene 
expression in the MT mice for the Pik3cg variants, except for a modest decrease (less 
than 3-fold) in Pik3cg v1 and Pik3cg v3 in the sciatic nerve. Therefore, our hypothesis for 
question one was not supported by our findings for Pik3cg. 
PTEN, a negative regulator of PI3K and a known tumor suppressor, was found to 
be significantly upregulated at the mRNA level in the BS of MT mice (Figures 8a; Table 
6). This upregulation of Pten during MT is consistent with other studies analyzing the 
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effects of morphine on Pten, which found Pten is upregulated in human and rat cell 
cultures during MT (Figure 3)(Yang et al. 2008). However, with most of the previous 
studies related to the role Pten plays in MT being reported in cancer cell lines, ours was 
one of the first to analyze its gene expression in vivo in the BS, SC, DRG, and SN (Yang 
et al. 2008). Interestingly, since Pten negatively regulates the PI3K/AKT intracellular 
signaling pathway, the upregulation of both Pten and PIk3cg v3 in the BS possibly 
suggests the upregulation of Pten may be attenuating the effects of Pik3cg v3 during MT, 
as Pik3cg is positively involved with analgesia created by opioids. Previous studies also 
found Pten to be upregulated during chronic morphine in the spinal cord dorsal horn 
(Yang et al. 2008). Overall, our findings support our hypothesis for question one in the 
BS, as an increase in Pten gene expression could negatively regulate the PI3K/AKT 
pathway.  
Recent studies have found that morphine can induce MOP dependent stimulation 
of AKT in mice DRGs. However, little is known about the specific AKT isoforms 
involved with opioid induced tolerance (Madishetti et al. 2014). Significant upregulation 
of Akt1, Akt2, and Akt3 was found in the BS, with varied expression among the other 
tissues (Figure 8b; Table 6). Akt2 was upregulated in the SN and downregulated in the 
DRGs, while Akt3 was upregulated only in the BS (Table 6). This varied expression 
among isoforms and tissues may be negligible, as these variations may just be noise. 
While Akt1 is involved with growth factor regulation, both Akt2 and Akt3 have been 
reported to be involved in MOP signaling, though only in regards to glucose uptake (Cho 
et al. 2001; Kim et al. 1999). Thus, our hypothesis was not supported for Akt as many of 
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the fold changes were insignificant in the SC, DRG, and SN. Additionally, the significant 
increases in the brainstem did not support the hypothesis, as we hypothesized Akt gene 
expression would decrease during MT. However, because AKT is phosphorylated, it may 
be more important to compare AKT phosphorylation activity across tissues. 
nNos1, or neuronal nitric oxide synthase, was found to be significantly 
upregulated (1.25-fold increase) in the BS of MT mice (Figures 8d; Table 6). Our 
findings are not consistent with question one, as we hypothesized nNOS1 would be 
downregulated during MT. Additionally, while NO and nNos have been extensively 
studied for their roles in nociception, there is a lack of information regarding gene 
expression changes in the BS. While we did not find any changes in SC nNos1 during 
MT, a past study found that the inhibition of nNos attenuated the development of 
morphine tolerance in spinal microglia (Liu et al. 2006). Another previous study found 
that under MT, activation of nNos1 reduced analgesia while nNos2 activation increased 
analgesia in mice (Kolesnikov et al. 2009). A previous study also found that the 
activation of KATP channels may be reliant on the activation of the nitric oxide pathway 
by morphine, which is initially dependent on the activation of PI3K/AKT pathway in 
mice (Cunha et al. 2010). While the study by Cunha et al. used non-MT tissues, their 
findings show the involvement of the PI3K/AKT pathway regarding opioid signaling. 
Therefore, while our gene expression results were not consistent with our hypothesis, the 
previous studies discussed above indicated there are activity level changes in nNos1 
during MT.  
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The gene expression of the KATP channels, specifically Kir6.x subunits (Abcc8, 
Abcc9, Kcnj8, Kcnj11v1, Kcnj11 v2) were varied across tissues (Table 6). The modest 
fold changes (less than three-fold) in KATP channel subunits among tissues suggests that 
morphine tolerance alone may not significantly alter KATP channel gene expression. 
Additionally, since the tissues we processed were not separated out by cell type, we 
cannot definitively say that the modest fold changes seen in the KATP channel subunits 
were from neurons and not potentially astrocytes and microglia, which have also been 
studied previously for KATP channel activity (Zhu et al. 2015). The non-significant gene 
expression changes in the KATP channel subunits does not support the hypothesis for 
question one, which hypothesized KATP channel expression would decrease during MT.  
Jnk3, or mitogen-activated protein kinase 10, was found by our lab to be non-
significantly upregulated in the SC and downregulated in the BS during MT, with all fold 
changes being less than two (Figures 8d and 9d; Table 6). Our findings did not support 
our hypothesis, as we hypothesized Jnk3 would decrease during MT. A few studies have 
analyzed Jnk3 during MT, suggesting that Jnk3 is upregulated during MT in the frontal 
cortex of a rat (Fan et al. 2003). Additionally, studies utilizing Jnk3 global knock out 
mice found an attenuation of morphine tolerance when the mice were given morphine, 
further demonstrating the role Jnk3 plays in opioid induced tolerance (Yuill et al. 2016). 
While their studies don’t correlate to the gene expression level changes in our results for 
Jnk3, it would be important to do a protein level analysis looking at phosphorylated JNK, 
as phosphorylated JNK3 may be expected to increase during MT (Figures 8d, 9d, 10d, 
11d).  
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Overall, the gene expression level differences in MT mice compared to saline 
mice suggest that the PI3K/AKT intracellular signaling pathway may be involved with 
the development of MT tolerance after chronic morphine exposure. Interestingly, our data 
suggests significant increases in Pik3cg v3, all Akt isoforms, and Pten (Table 6). These 
results, except for Pten, did not support our hypothesis of downregulation of the 
PI3K/AKT pathway during MT. Additionally, our conclusions from the RT-qPCR data 
are limited as the significant differences in gene expression witnessed were all modest 
changes with a fold change less than three. Furthermore, our conclusions from our gene 
expression analysis of MT mice are further limited, as we focused on genes with 
significant changes in gene expression. It is completely possible that a non-significant 
change in gene expression may be more important than a significant change in gene 
expression that is still less than two-fold. Finally, our conclusions are overall limited as 
gene expression differences do not illustrate the changes in protein, enzyme, or 
phosphorylation activity that may be occurring during MT. Thus, while the gene 
expression analysis of the MT tissues revealed significant upregulation within the 
PI3K/AKT intracellular signaling pathway in the BS, protein level and phosphorylation 
state changes for these variants and isoforms under these same conditions still need 
confirmation. 
2. MT cGMP Nucleotide Levels Decrease in the SN 
Commonly acting as a secondary messenger, cGMP is known to be involved with 
apoptosis and ion channel conductance, and is responsible for activating protein kinase G 
in the PI3K/AKT pathway (Bolaños et al. 2008; Chai, Zhang, and Lin 2011; Lincoln, 
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Dey, and Sellak 2017). cGMP nucleotide levels were significantly lower for the MT mice 
than the saline mice in the SN (Figure 12, Table 8). Comparing our cGMP results with 
our gene expression data, it is interesting to note that while we saw the most significant 
changes in gene expression in the brainstem, the only reported significant change in 
cGMP nucleotide levels was a decrease in the SN. While we would expect to see a 
majority of the changes in the same tissue, our results indicate otherwise. This expected 
relation may be masked by both the low fold changes and the high SEM values for many 
of the genes. Therefore, a larger sample size may be able to identify more subtle changes 
in both gene expression and cGMP nucleotide levels. Additionally, a previous study 
found cGMP gene expression is upregulated approximately two fold in the SC after 
chronic morphine exposure, which did not correlate to the cGMP nucleotide changes seen 
with our SC data (Liang and Clark 2004). Since the tissues we processed were not 
separated out by cell type, we cannot rule out the possibility that the fold changes seen in 
the cGMP nucleotide levels were from cells such as astrocytes and microglia, and not just 
neurons. Additionally, the role cGMP plays in analgesia and morphine tolerance is up for 
debate, as the NO-cGMP-PKG pathway has been shown to be involved with the 
induction of both analgesia and pain (Longhi-Balbinot et al. 2016; Quock et al. 2011; 
Sung et al. 2017; J. Wang et al. 2008). Overall, while there may be differences in cGMP 
levels among nervous system tissues, the changes in cGMP levels in MT mice vs saline-
treated did not support our hypothesis except for the SN, as we hypothesized cGMP 
levels would decrease during MT. 
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MT+SNL mice vs Saline-Treated Mice  
1. No Change in TPWL for Ipsi and Contra MT+SNL Mice 
The morphine tolerant mice with a spinal nerve ligation (MT+SNL) had no 
significant differences in reaction times for both the uninjured (contra) and injured (ipsi) 
sides (figure 13). Comparing the MT and saline-treated mice TPWL data to the MT+SNL 
data, the non-SNL morphine treated mice had a higher overall TPWL, which may be 
attributed to the lack of the SNL. Additionally, a reduction in TPWL time on the ipsi side 
versus the contra side could be expected, as the ipsi side has both the inflammation and 
the hyperexcitability of the L5 and L6 from the ligation of the L4 spinal nerve (Kitagawa 
et al. 2005). The decrease in TPWL helps to support our hypothesis for question two, as 
the addition of the SNL lowered the reaction times of the mice further than the non-SNL 
MT mice.  
2. MT+SNL Gene Expression Decreases in the SC and Varies in Other Tissues 
Gene expression levels in the BS, SC, DRG, and SN of MT+SNL (ispi and contra) vs 
saline mice were analyzed. This discussion section related to gene expression fold 
changes is separated out by gene. Our lab found significant increases in the KATP channel 
subunits gene expression in the BS, decreases in all of the genes except Pten in the spinal 
cord, varied expression in the DRG, and non-significant increases in the sciatic nerve 
(Figures 8-11; Table 6). Overall, the changes in gene expression supported our hypothesis 
for question two only for the SN, as we hypothesized gene expression would decrease in 
MT mice with SNL. Additionally, looking at the fold changes for the MT+SNL mice, 
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many were larger than two-fold, with the KATP channels in the SN reaching 3000-fold 
increases in some cases.  
There were significant decreases in gene expression for PIk3cg v1 and Pik3cg v2 
in the brainstem and spinal cord, with the dorsal root ganglia showing a significant 
increase in the contra side of Pik3cg v2 (Figures 14a, 15a, & 17a; Table 13). These 
results do not support our hypothesis for all Pik3cg variants, as we hypothesized Pik3cg 
would decrease under MT in SNL mice. Additionally, when comparing the Pik3g variant 
gene expression for MT+SNL mice back to MT mice, there were large differences in fold 
change (Figures 8-11, 14-17). One possible explanation for this drastic change could deal 
with previously published reports analyzing the role PIK3CG plays in inflammation 
signaling, with inhibition of PIK3CG shown to reduce the severity of inflammation by 
lowering activation and recruitment of immune cells (Hawkins and Stephens 2015). 
Thus, the addition of the SNL to the MT model may help to explain the increases in gene 
expression in the PNS. However, with the inability of being able to measure gene 
expression in acute morphine (less than 48hrs after morphine injections) SNL mice and 
the lack of data for saline treated SNL mice for all of the genes, it is not possible to rule 
that SNL alone is the sole cause of the massive fold change differences seen within the 
MT+SNL mice.  
We were the first to report an increase in Pten in the PNS with varied expression 
in the CNS tissues, however, the large SEM values limit the conclusions we can draw 
from our data (Figures 14a, 15a, 16a, & 17a; Table 12). Thus, our results do not support 
our hypothesis as Pten was hypothesized to significantly increase during MT+SNL.  
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Additionally, these findings were not supported by a rat spinal cord injury study that 
found Pten gene expression levels to be significantly increased in the spinal cord 30 days 
post injury (Povysheva et al. 2018). The lack of increase in gene expression in the spinal 
cord of our MT+SNL model compared to the spinal cord injury model may be due to the 
tissue that was injured, as our study ligated the sciatic nerve and the Povysheva et al. 
study injured the spinal cord. Most interestingly, the expression level of Pten was 
upregulated in the BS of MT mice, but downregulated in the BS of MT+SNL (Figures 8a 
& 14a). The decrease in gene expression with the addition of the SNL (less than 66.67-
fold decrease for both ipsi and contra) suggests the upregulation seen during morphine 
tolerance (1.93-fold increase) is attenuated with the addition of the SNL. More 
experiments, including protein level analysis, should be performed to further analyze 
these findings. 
All Akt isoforms except Akt1 had significantly decreased gene expression in the 
BS, while all isoforms decreased in the SC, increased in the SN, and had varied 
expression in the DRGs of MT+SNL mice (Figures 14b, 15b, 16b, &17b; Table 13). 
Therefore, our hypothesis for question two was supported for all Akt isoforms in the SC 
and Akt2 and Akt3 in the BS, as we hypothesized all isoforms of Akt would decrease 
during MT with SNL. Our results were consistent with an article that found an increase in 
Akt expression in the SN of mice after SNL (Murashov et al. 2001). However, that study 
fails to separate out the differences in the Akt isoforms that we addressed in our 
experiment. In the SN of MT+SNL mice, Akt1 was >10 fold higher than Akt2 and Akt3. A 
paper investigating olfactory nerve ligations in Drosophila suggests Akt1 is upregulated 
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around the site of the injury and is believed to be involved with removal of axonal debris 
(Musashe et al. 2016). While not completely correlational, the increases in Akt1 gene 
expression over the other two isoforms may be because of its involvement with removal 
of axonal debris. Additionally, further analysis should be done looking at AKT 
phosphorylation during MT+SNL, as while our results indicate a decreased expression of 
the Akt isoforms in the spinal cord, there are previous reports that found phosphorylated 
AKT increases in the spinal cord during neuropathic pain induced by sciatic nerve 
transection in rats (Guedes et al. 2008).  
Our results also show KATP channel expression is different among all tissues 
(Table 13). The BS saw a significant increase in all KATP subunits except contra Kcnj8, 
with the SC seeing significant decreases in Abcc9, Kcnj11 v2, and ipsi Kcnj11 v1. In the 
SN, all KATP subunits were upregulated in MT+SNL mice, while the DRGs saw varied 
expression. These results only partially support our hypothesis that the KATP channel 
subunits would decrease, as the only tissue to see significant decreases in gene expression 
was the SC. Additionally, our results are mostly inconsistent with a previous paper that 
found KATP channels to be downregulated in the DRGs of rats with a SNL at the L5 and 
L6 (Zoga et al. 2010). Our results were also not completely consistent with a previous 
report that found Abcc8, Kcnj11 v1, and Kcnj11 v2 to be downregulated in both the dorsal 
root ganglia and spinal cord (Figures 15c & 16c) (Luu et al. 2019). In the injured (ipsi) 
SN, many of the KATP subunits were substantially lower than their contra counterparts. 
These findings suggest that in the site of injury, KATP channel activity may be reduced, 
potentially reducing the chance of hyperpolarization and analgesia. Additionally, the 
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large fold changes seen were mostly non-significant due to large SEM values. Many of 
the fold changes for the KATP channel subunits were greater than 10-fold, with some even 
reaching 3000-fold. Therefore, while these large fold changes may not be statistically 
significant, we cannot rule out whether their drastic fold changes are important for MT 
mice with SNL.  
Jnk3 was significantly downregulated in the SC and upregulated in the BS, with 
upregulation in the SN and downregulation in the DRG (Figures 14d, 15d, 16d, & 17d; 
Table 13). We hypothesized Jnk3 would be significantly upregulated during MT+SNL, 
which was supported only in the BS. Our results are inconsistent with an SNL study in 
rats, as their results show Jnk is upregulated in the SC after SNL (Zhuang et al. 2006). 
These inconsistencies could be because while they observed overall Jnk expression, our 
study focused on Jnk3. Additionally, we also analyzed the effects of MT using our SNL 
model, while their study solely looked at the effects of SNL. Comparing Jnk3 ipsi and 
contra expression across tissues, a sizable increase in expression was found in the SN on 
the contra side versus the ipsi side. This is an interesting find as the side with the injury 
had a lower gene expression than that of the non-injured side. Furthermore, the lower 
gene expression in the injured side vs uninjured side further contradicts our hypothesis 
that Jnk3 expression would increase during MT+SNL. Further analysis looking at 
phosphorylation states of JNK3 would be useful to further understand why contra had 
higher gene expression. 
Oprm1, the MOP gene, decreased in the SC and increased in the BS, DRG, and 
SN for both ipsi and contra MT+SNL mice, which contradicts our hypothesis that Oprm1 
86 
 
would significantly decrease during MT+SNL (Table 13). These results are mostly 
consistent with a study that found ipsi Oprm1 activity to be two-fold lower in L5/L6 SNL 
mice (Kiso et al. 2008). When comparing the MT+SNL mice to MT mice, Oprm1 
activity in the MT+SNL mice had greater fold changes compared to the MT mice (Tables 
6 & 13). These large differences in fold change suggest that we cannot disregard the 
possibility that the SNL, and not the combination of the MT and SNL may be 
responsible, for the entirety of the changes witnessed. Thus, the addition of SNL to MT is 
useful for understanding how chronic neuropathic pain may affect MT.  
A decrease in nNos1 gene expression was present in the SC, with an increase in 
gene expression in PNS tissues and the BS for both ipsi and contra MT+SNL mice (Table 
13). Comparing back to our hypothesis that nNos1 would decrease in MT+SNL mice, our 
results support the hypothesis for only the SC. Our results are also consistent with an 
nNos activity study in rats with SNL, which found nNos activity decreases in the SC after 
SNL (Yang, Kim, and Lee 2007). Previous studies have also shown nNos to be involved 
with morphine tolerance, as inhibition of nNOS through p38 modulation attenuated the 
development of morphine tolerance in mice (Liu et al. 2006). Overall, with nNos being 
involved with insulin secretion, angiogenesis, and neural development, further analysis of 
nNOS1 at a protein level would help further understand the role nNOS1 plays in the 
development of MT. 
Overall, our data for the RT-qPCR of MT+SNL mice did not completely support 
our hypothesis (except for in the SC) that the PI3K/AKT pathway would be 
downregulated during MT+SNL. These results point out a few noteworthy caveats of this 
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experiment. First, the downregulation of the PI3K/AKT pathway may be tissue 
dependent as there was decreased gene expression in the SC and increased expression in 
the SN. Second, while many of the largest fold changes were non-significant due to large 
SEM values, we are unable to rule out that many of the non-significant changes are not 
important for the development of MT. Finally, gene expression analysis is limited as it 
may not completely correlate to how a mouse responds to stimuli under morphine 
tolerance, as there are many other enzyme, protein, and phosphorylation processes 
occurring. Thus, the changes in gene expression listed within for both MT+SNL and MT 
mice, whether significant or non-significant, cannot answer the entire story of how the 
PI3K/AKT pathway is involved with the development of morphine tolerance.  
3. MT+ SNL cGMP Nucleotide Levels Increase in SC and Decrease in SN 
cGMP nucleotide levels were significantly increased in both ipsi and contra SC of 
MT+SNL mice and substantially decreased in the SN when compared to saline mice 
(Figure 18, Table 15). These results support our hypothesis for only the SN, as we 
hypothesized cGMP would decrease in MT+SNL mice. The MT+SNL results are 
different than that of the MT mice, suggesting nerve injury, in conjunction with morphine 
tolerance, exhibits a larger effect on cGMP nucleotide levels. Previous studies found that 
peripheral nerve injuries of the SN in rats increased spinal cGMP levels, which supports 
our findings in the SC (Siegan, Hama, and Sagen 1996). Additionally, our findings are 
further supported by current and past pain mechanism theories that suggest production of 
cGMP is stimulated by the activation of NMDA receptors through activation of NO and 
guanylate cyclase, and is believed to be required for the development of hyperalgesia 
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(Meller and Gebhart 1993). Comparing our findings to MT+SNL RT-qPCR data, it is 
interesting that while gene expression decreases in the SC and increases in the SN, cGMP 
nucleotide levels increase in the SC and decrease in the SN. The flip between gene 
expression and cGMP levels is unexpected, as it may be believed that the changes may be 
consistent with tissues. One possible explanation for the increase of cGMP in the SC may 
be that cGMP is recruited to the SC after SNL, as there were relatively no changes for the 
rest of the tissues except the SN in both the MT and MT+SNL tissues. Additionally, the 
conclusions we can draw from these results are limited as the changes in cGMP 
nucleotide levels may not actually correlate to the behavior differences seen in the 
MT+SNL mice during TPWL tests. 
PI3K Pathway Inhibitors 
1. All Pathway Inhibitors Attenuated Morphine Tolerance by Day 5 
PI3K pathway inhibitors increased TPWL by the fifth day when compared back to the 
vehicle-treated mice. Quercetin (PIK3cg inhibitor) appeared to have the greatest overall 
effect (increase) on TPWL (Figure 19). This result was supported by a study that 
analyzed quercetin’s effects on thermal hyperalgesia in diabetic mice, which found 
quercetin increased tail-flick latencies compared to their vehicle (0.5% sodium carboxy 
methylcellulose) (Anjaneyulu and Chopra 2003). This study also found that with the 
addition of naloxone, an opioid receptor antagonist, the increase in the nociceptive 
threshold seen in diabetic mice given quercetin was inhibited. As their results align with 
our findings, we can conclude quercetin not only helps prevent morphine tolerance in a 
diabetic neuropathy model, but also in a SNL model. Looking at our RT-qPCR data for 
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the MT+SNL, all Pik3cg variants except for Pik3cg v1 decreased in all tissues. This 
suggests that inhibiting PIK3cg could potentially exacerbate or have no effect on 
morphine tolerance. However, the results of the TPWL study with quercetin found that 
not to be the case. Thus, our findings did not support our hypothesis as we hypothesized 
inhibiting the PI3K/AKT pathway (except for JNK and PTEN) would have no effect or 
exacerbate morphine tolerance.  
Thalidomide, a glutamic acid derivative, has recently been reintroduced into 
clinical settings to treat neurological disorders (Khan et al. 2017; Klausner, Freedman, 
and Kaplan 1996). Using thalidomide prior to morphine injections, we found thalidomide 
reduced the development of opioid induced tolerance (Figure 19). Our results were 
supported by a recent study analyzing thalidomide’s effect on analgesic tolerance in 
mice, which found thalidomide lessened the development of morphine tolerance (Khan et 
al. 2017). Additionally, Khan et al. also found that thalidomide, in conjunction with a 
NOS inhibitor, reversed the morphine tolerance attenuation effect of thalidomide. 
Looking further into the inhibition of NOS, Khan et al. found inducible NOS (iNOS), 
which is involved in immune system responses, is overexpressed in mice given 
thalidomide and morphine. This result helps to explain why our MT mice did not see a 
high upregulation of nNos, as the inducible Nos may play a larger role in morphine 
tolerance than the neuronal Nos. Thalidomide has also been shown to be involved with 
the inhibition of TNF-α, which is a mediator of the inflammatory immune response 
(Klausner, Freedman, and Kaplan 1996). This is important to note for the MT+SNL mice, 
as the ligation of the spinal nerve creates an inflammatory response which can contribute 
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to the hyperexcitability of a neuron. Thus, the effects of thalidomide on MT may be 
exacerbated due to its ability to also reduce inflammation. Additionally, looking at our 
RT-qPCR data for the MT+SNL, all Pik3cg variants except for Pik3cg v1 decreased in all 
tissues. This suggests that inhibiting PI3K could potentially exacerbate or have no effect 
on morphine tolerance. However, the results of the TPWL study with thalidomide found 
that not to be the case, suggesting that the inhibition of other catalytic PI3Ks such as 
PIK3CA or PIK3CB may be involved in morphine tolerance. Thus, our findings did not 
support our hypothesis, as we hypothesized inhibiting the PI3K/AKT pathway (except for 
JNK and PTEN) would have no effect or exacerbate morphine tolerance.  
SP600125, a JNK phosphorylation inhibitor, reduced the development of 
morphine tolerance (Figure 19). Our results were consistent with a past study that 
analyzed the effects of JNK inhibition of MOPs and found SP600125 inhibited the JNK 
activation and prevented the development of MT (Melief et al. 2010). Additionally, our 
hypothesis was supported for question 3, as SP600125 inhibition of JNK attenuated 
morphine tolerance. Specifically related to our research, the development of analgesic 
tolerance was blocked through the inhibition of JNK. Interestingly, this result was 
reversed for other opioids, including fentanyl and methadone, suggesting different classes 
of opioids can have varied downstream effects that may act on different pathways than 
the PI3K/AKT pathway. Additionally, the inhibition of morphine tolerance using 
SP600125 was consistent with a study that used mice with chronic constriction of the 
sciatic nerve given morphine (Hervera, Leánez, and Pol 2012). When comparing these 
results to the gene expression results of Jnk3 for MT+SNL mice, Jnk3 expression 
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decreased for all tissues except the BS. However, our gene expression only looked at 
Jnk3 and not whether the kinase changes phosphorylation states during MT+SNL. 
Looking at the PI3K/AKT pathway, cGMP activates PKG, which can then activate either 
KATP channels or JNK through ROS/Calmodulin/CaMKII signaling (Chai, Zhang, and 
Lin 2011).  Therefore, we hypothesize the inhibition of JNK phosphorylation may 
redirect ROS/Calmodulin/CaMKII signaling to the KATP channels. Further analysis of 
JNK phosphorylation states would assist in confirming this hypothesis. 
Future Directions 
Our research into the PI3K/AKT intracellular signaling pathway gene expression 
offers another look into how this pathway may be involved with the development of 
opioid induced tolerance. Two potential further areas of interest for protein level analysis 
are AKT and JNK. Previously published papers analyzed the effects of morphine 
tolerance on AKT phosphorylation and found AKT phosphorylation increases during 
morphine tolerance in mice (Lutz et al. 2015; Xu et al. 2010). These papers did not 
incorporate a chronic pain model or analyze various tissues from both nervous systems, 
leaving a potential area for future research progress that could be compared back to the 
neuropathic chronic pain with morphine tolerance work we performed. JNK is also an 
interesting target for further analysis as a recent paper analyzing the effects of morphine 
tolerance on global Jnk3 knockout mice found a reduction in morphine tolerance 
compared to wild-type mice (Yuill et al. 2016). Therefore, analyzing protein levels of 
JNK3 (including phosphorylation states) and Jnk3 knockout mice with a spinal nerve 
ligation with TPWL behavior tests could be promising future directions to further 
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understand the PI3K/AKT pathway’s involvement in morphine tolerance. Additionally, 
understanding the changes that occurs to individual proteins in the PI3K/AKT pathway 
during MT and MT+SNL may also advance research in other areas besides morphine 
tolerance research, as proteins in our project were also found to be involved in neuronal 
growth (nNOS1). Therefore, our research has both clinical and basic science implications 
that can further the knowledge of morphine tolerance and morphine tolerance with 
underlying neuropathic pain due to nerve damage. 
Conclusion 
To develop new analgesic medications that mitigate opioid induced tolerance and 
hyperalgesia, there needs to be a greater understanding of the downstream signaling 
targets of MOPs. With the opioid epidemic continuing to be a major clinical problem 
within the United states, our work on the PI3K/AKT intracellular signaling pathway 
could aid in the development of new, targeted opioid therapies that include drugs that 
also inhibit the development of opioid induced tolerance. Our results suggest there is a 
link between the expression of the PI3K/AKT intracellular signaling pathway and the 
development of morphine tolerance in mice with and without a spinal nerve ligation. 
Pharmacological inhibition of the PI3K/AKT pathway was also shown to attenuate the 
development of morphine tolerance over a five-day period. Overall, the results from the 
data illustrated within conclude the PI3K/AKT intracellular signaling pathway is a 
potential target for reducing the development of morphine tolerance. While our initial 
hypothesis of downregulation of the PI3K/AKT pathway during morphine tolerance may 
not have been completely supported by our results, continued research into this pathway 
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will advance our understanding of morphine tolerance and potentially contribute to the 
development of new analgesic drug therapies.  
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